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Equine bone marrow-derived mesenchymal stromal cells (MSCs) and adipose 
tissue-derived stromal cells (ASCs) were compared for frequency within their respective 
tissues, cell doubling characteristics and differentiation multipotential in culture based on 
histochemical staining and compositional analysis. Equine MSCs and ASCs from young 
adult horses were harvested and isolated from sternal bone marrow and supragluteal 
subcutaneous adipose tissue, respectively, and grown up to passage 10 (P10) to determine 
cell doubling characteristics. Limit dilution assays were performed on primary and 
passaged (P2, P4) MSCs and ASCs to determine the frequency of colony forming units 
with a fibroblastic phenotype (CFU-F), and the frequency of MSC differentiation into 
adipocytes (CFU-Ad) and osteoblasts (CFU-Ob). Pellet cultures of MSCs and ASCs at 
P2 were performed in chondrogenic media with or without transforming growth factor 
(TGF-β3) and bone morphogenic protein (BMP-6). Collagen type II expression, 
glycosaminoglycan and DNA content and pellet size were measured. 
Primary MSCs doubled more slowly than subsequent MSC passages (DT = 4.9 ± 
1.6 days compared to 1.4 ± 0.22 days). Doubling time of ASCs (2.1 ± 0.9 days) was 
significantly slower than that of MSCs. Primary MSC frequency was 1 in 4,224 ± 3,265 
nucleated BM cells while the frequency of ASC was 1 in 2.3 ± 0.4 nucleated stromal 
vascular fraction cells. Primary and subcultured MSCs showed robust adipogenic and 
osteogenic differentiation potential. MSC pellet cultures developed collagen type II 
expression by Day 7 and hyaline matrix by Day 14. ASC pellets only exhibited mild 
matrix or collagen formation under electron microscopic examination but showed no 
immunohistochemical expression of collagen type II.  MSC pellets supplemented with 
xiii 
 
growth factors were larger (p <0.0033) and showed significant increases in GAG 
concentration by Day 14 compared with all other pellets of both cell types (P<.0001).  
The frequency, in vitro growth rate, and adipogenic and osteogenic differentiation 
potential of young adult horses are similar to those documented for MSCs of other 
species, whereas in vitro growth rate of ASCs differs from human ASCs. MSCs show 
earlier osteogenesis compared with ASCs and more robust chondrogenesis in the 













CHAPTER 1.  
A REVIEW OF FUNDAMENTAL CONCEPTS IN STEM CELL BIOLOGY AND 






1.1 Introduction to Stem Cell Biology: Definitions and Nomenclature  
Stem cells are functional units responsible for generation of embryonic and adult tissue.1 
The description of stem cells dates back to the 19th century, when Edmund Beecher Wilson 
described the term as synonymous to a mitotically quiescent primordial germ cell.2 However, the 
bulk of the research into the biology of mesenchymal stem cells started well over forty years ago 
when Friedenstein and his coworkers showed that bone marrow derived cells could differentiate 
into cell of mesenchymal origin, such as osteoblasts.3 During that time it was also shown that 
demineralized bone or bone extracts were capable of causing cartilage or bone formation when 
implanted either subcutaneously or intramuscularly.4-6  During the 1970s Caplan and his 
coworkers demonstrated that mesenchymal cells from embryonic stage 24 chick limb buds could 
be isolated and were able to differentiate in vitro into various mesenchymal tissues such as bone, 
cartilage and muscle. Later it was found that exposure of these limb bud cells to demineralized 
bone extracts would induce chondrogenic differentiation in a dose-dependent fashion, which lead 
to the isolation of a demineralized bone crude extract with known dose dependent “chondrogenic 
stimulating activity” (CSA). This protein was isolated, purified and characterized as a 
heterodimer of what are now known as bone morphogenic proteins.5,7-10  
These chick limb bud mesenchymal cells and the presence of CSA in demineralized bone 
extracts as well as the aforementioned work by Urist and coworkers lead to the suspicion that 
mesenchymal stromal cells also exist in adult tissues, which appeared consistent with the 
enhanced  efficiency of fracture repair when fresh bone marrow was used in large bone defects.5 
Further support of this theory was work by Friedenstein11 and Owen12,13 that showed that bone 
marrow-derived cells are capable of adhering to petri dishes and appeared to have osteogenic and 
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adipogenic potential. This work set the stage for exploring the potential of adult mesenchymal 
stromal cells (MSC) from varying tissue sources for the purpose of regenerative tissue repair. 
1.1.1 Nomenclature of Mesenchymal Stromal Cells (MSCs) 
For many years, the literature has published a confusing variety of different terminology 
in its description of stem cells from different tissue sources.14 The property of bone marrow-
derived mesenchymal stromal cells to adhere to the plastic culture dish prompted the original 
descriptive name of ‘plastic-adherent progenitor cells’.15 The literature often refers to the bone 
marrow-derived stem cells with plastic adhering properties as mesenchymal stem cells, which 
became popular through Arnold Caplan’s work and descriptions.16 However, it has been shown 
that not all of these mesenchymal cells are in fact multipotent. Pittenger17 and his coworkers 
showed that merely 70% of the unfractioned nucleated cell pool of marrow-derived cells was 
capable of adipogenic, osteogenic and chondrogenic differentiation whereas the remainder of the 
cells did not undergo chondrogenic differentiation. Hence it was concluded during the Annual 
Meeting of the International Society for Cellular Therapy (ISCT) in 2000 that there is 
insufficient evidence that all unfractioned fibroblast-like adhering cells have stem-like activity.18 
It is generally accepted that unlike normal fibroblasts, such as those of dermal origin, those 
isolated from bone marrow by plastic adherence have a multipotential biological properties but 
are not a uniform population of cells. In fact, only a very small proportion of the marrow-derived 
nucleated cell pool is capable of forming a colony-forming unit of fibroblasts (CFU-F) 
demonstrating multipotential. Therefore, it has been proposed by Horwitz and coauthors to name 
these cells multipotent mesenchymal stromal cells and suggest that only cells that have met 
specified stem cell characteristics may be termed ‘mesenchymal stem cells’; this compromise 
ascribes the popular ‘MSC’ acronym to both cell populations and maintains continuity within the 
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literature.19 However, in the context of stromal cell descriptions from multiple tissue sources, the 
term ‘mesenchymal stromal cell’ and its common acronym MSC, which merely refers to the 
embryological origin of this cell type, can create confusion. If the cell is derived from bone 
marrow it may be appropriately called BMSC, which is also a common acronym of these cells, in 
order to distinguish the origin of this type of MSC from those of other origins.  
Nomenclature from stromal cells of adipose tissue varies widely14 including descriptions 
such as adipogenic reticular cell20, mesenchymal cell21, fibroblast, stromal cell and adipose-
derived adult stem cell (ADAS).22 A recent consensus reached at the Second Annual 
International Fat Applied Technology Society meeting (IFATS, October 3-5, 2004, Pittsburgh, 
PA) was to use the acronym ‘ASC’ for adipose-derived stromal cells23 or adipose-derived stem 
cells.24  
1.1.2 Stem Cell Definition and Self-renewal  
Stem cells are clonogenic in nature capable of repeated cell division over many 
generations without differentiation into a specific cell lineage. Genetic characteristics and 
environmental cues such as cytokines, transcription factors, cell-to-cell or cell-to-matrix 
interactions are believed to direct stem cells into a committed precursor cell lineage, which then 
gives rise to mature progeny cells, which include nonrenewing progenitor cells and terminally 
differentiated effector cells.25 Whether stem cells truly maintain absolute self-renewal potential 
remains controversial. Marrow-derived MSCs have been shown to have a highly variable self-
renewal potential in culture.26,27 Friedenstein and his coworkers11 have shown that the cyclic 
division known to occur in cell culture is not characteristic for cells in vivo. The cue for stem 
cells to enter into the cell cycle appears to depend on serum growth factors and the addition of 
increased concentration of growth factors such as the fibroblast growth factor-2 (FGF-2). This 
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can cause expansion rates of more than 50 population or cell doublings (CD) compared with 
control basal media cultures, which are usually bound by senescence to less than 50 CDs as 
postulated by the Hayflick limit, which is discussed later.28,29  
Another factor, which appears to effect the expansion rate a well as maintenance of 
multipotentiality of human mesenchymal stromal cells, is lowering the seeding density of cells in 
culture.27,30 Colter and coworkers showed dramatic differences in expansion rates when cells 
were seeded at low compared with high densities.27 This work is supported by a recent report, 
which showed that human bone marrow-derived MSCs seeded at 10 cells/cm2 expanded 
approximately 500-fold within 12 days with a maximum cell doubling time of approximately 10 
hours.31  When the same cells were seeded at 1,000 cells/cm2, they expanded only 30-fold, which 
merely resulted in a 5-fold greater final cell count relative to the low density plating. The effect 
of seeding density on the differentiation potential of cells was illustrated by Sekiya31 and his 
coworkers who showed that after adipogenic induction of passage 3 human MSCs caused 
significant reduction in absorbance levels for Oil Red O after isopropyl alcohol extraction when 
cells were seeded at 1,000 cells/cm2 compared with those seeded at 50 cells/cm2.   
The growth characteristics of MSCs depend on the species and the tissue origin. 
Mesenchymal stromal cells derived from bone marrow show an initial lag phase of cell 
proliferation in primary culture, which accelerates through a log phase and eventually plateaus.26 
Cell doubling times of MSCs derived from bone marrow vary slightly among species, reported 
as approximately every 48 hours for dogs32 and Rhesus Macaques33 whereas human postnatal 
MSCs require approximately 24 hours.34 Furthermore, age-related decreases in growth rates have 
been reported for intestinal stem cells using an irradiation model to simulate tissue aging in 
mice35. Also differences between the in vitro culture conditions, including the concentrations of 
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fetal bovine serum or the use of other serum substitutes such horse serum, have to be an 
important consideration in the comparative assessment of cell growth characteristics as 
determined in separate publications. 
1.1.3 Stem Cell Replicative Control  
Exciting new research in recent years has begun to elucidate the complex regulatory 
control mechanisms that are involved in stem cell self-renewal. This process is believed to be 
directed by cell intrinsic factors, epigenetic control, small RNA regulators, and cell-extrinsic 
signals. Among the intrinsic transcription factors are orphan nuclear receptor TLX, polycomb 
transcriptional repressor Bmi1, high-mobility-group DNA binding protein Sox2, and basic helix-
loop-helix Hes genes.36 Epigenetic control occurs through histone modifying enzymes and 
chromatin remodeling proteins37 whereby histone modification can involve acetylation, 
methylation, phosphorylation, ubiquitylation, sumolyation and ADP-ribosylation.38 Histone 
acetylation has been most thoroughly examined and is regulated by histone acetylases (HATs) 
and histone deactylases (HDACs). It has been shown that HDAC-mediated transcriptional 
repression occurs through deacetylation of histone lysine residues and thereby restricts access of 
transcription factors to their target genes. These processes are believed to be essential for the 
maintenance, replication, and differentiation of neuronal stem cells.36  
More recently the epigenetic control of self-renewal through histone methylation has 
gained attention.39,40 The mechanism occurs through chromatin modifications of target genes 
assuming a  bivalent conformation facilitated by histone methylation, which is a dynamic process 
regulated by methyl transferases and demethylases. Transcriptional control of self-renewal in 
neuronal stem cells is closely related to the degree of lysine methylation leading to either mono-, 
di-, or tri-methylated histones. Gene-specific ‘active’ or ‘repressive’ methylation complexes are 
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then responsible for inducing replicative capacity through histone H3 lysine 4 (H3K4) 
methylation, as seen in embryonic and neuronal cells. In contrast, repressive neuronal stem cell 
genes carry histone H3 trimethyl K9 and histone H3 monomethyl K20 as well as histone H3K27, 
of which the latter has also been reported for embryonic stem cells. The methylation status is 
also linked to the differentiation capacity of stem cells whereby histone H3 trimethyl K20 has 
been found abundantly in differentiation neuronal stem cells.36,37  These methylation 
modifications are known to occur on target genes downstream to transcription factors Oct4, 
Nanog, c-Myc, Klf4 and Sox2, which have been shown to be able to reprogram fibroblasts to a 
pluripotent state and are therefore believed be important upstream regulators of the self-renewal 
mechanism.37,41 
Cellular processes including development, proliferation, and differentiation are also 
controlled by small non-coding RNAs. A large family of the small non-coding RNAs recently 
identified, are the miRNAs (micro-RNA) which are single-stranded fragments transcribed by 
RNA polymerase II from miRNA genes (class II genes) and are known as negative regulators of 
eukaryotic gene expression. Primary transcripts of miRNA, called pri-miRNAs, are converted 
inside the nucleus to pre-miRNAs, which are hairpin precursors extruded into the cytoplasm 
where they cleaved into mature miRNAs. These miRNAs are then complexed to an RNA-
induced silencing complex (RISC) and presented to target mRNAs leading to their cleavage and 
subsequent translational repression. It is believed that about one-third of all animal genes are 
regulated by miRNAs and of all miRNAs thus far identified the majority (70%) appears to occur 
in the brain, suggesting their importance in neuronal function.42-44 
Cell-extrinsic signals occur through direct physical interactions between stem cells and 
their biological niches are are soluble factors, which include Wnt, Notch and Sonic hedgehog 
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(Shh).36 The Wnt/β-catenin signaling has been shown to be important in the proliferation 
pathway of neuronal stem cells through downstream targets such as cyclin D1.45 Also Wnt3a and 
Wnt5a have both been associated with stimulation of murine neuronal precursor cell proliferation 
and differentiation.46 Notch signaling occurs by direct binding of a Notch ligand of one cell to 
the Notch receptor of an adjacent cell, which facilitates the release of the intracellular Notch 
domain and its translocation into the nucleus where it causes downstream effector expression 
such as for genes of the Hes family.47,48 Notch is believed to maintain the self-renewable state of 
stem cells.49 Finally, the sonic hedgehog (Shh) gene also is considered an important neural 
progenitor cell mitogen in both the embryonic and adult brain maintaining cell proliferation 
through mediation by the zinc finger-containing transcription factor Gli1. 
Finally, it is believed that receptor tyrosine kinase signaling regulates stem cell 
proliferation and self-renewal, controlled in part by extracellular ligands such as transforming 
growth factor-alpha (TGFα), epidermal growth factor (EGF), and fibroblast growth factor 
(FGF).50-53 It has been postulated that neuronal stem cells may be influenced by other 
extracellular signals such as the Wnt, Notch and Shh derived from neighboring cell types, such 
as astrocytes and neuroblasts, as well as ependymal and endothelial cells through interaction with 
intrinsic signaling pathways such as the Wnt/-catenin-cyclin D1, Notch-hes1/5 and Shh-
Gli1.36,54-56 
1.1.4 Definition of Stem Cell Potency  
Stem cells are categorized into classes of potency: (1) Totipotent cells such as those in a 
fertilized egg are capable of forming an entire organism and are therefore able to give rise to any 
embryonic and extra-embryonic cell type; (2) Pluripotent cells are capable of forming tissues of 
all embryological origins such as endodermal, mesodermal and ectodermal tissues; whereas (3) 
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multipotent cells, such as mesenchymal stromal cells of bone marrow17,57,58, are believed to be 
restricted to the differentiation of one or more cell types within a single embryological germ 
layer, and therefore limited to formation of mesenchymal tissues such as blood, fat,17 bone,26,59 
cartilage,57 and muscle60. However, MSCs have also been reported to form tissues such as liver61 
and lung,62 which are considered of endodermal origin or nerves,17,58,63-65 which are ectodermal 
tissue. Therefore, the mesenchymal cells may have greater pluripotentiality than originally 
thought.  
1.1.5 Stem Cell Plasticity 
The differentiation process was traditionally believed to be a progressive downstream 
commitment and irreversible in nature. However, more recently studies have challenged this 
concept suggesting that once stem cells have ‘committed’ themselves to a specific cell lineage, 
they may still be able to transdifferentiate into another cell lineage. This would support a more 
flexible system in which cells may quickly respond to changing regenerative cues in the 
microenvironment of healing tissues.66  Song and his coworkers reported that once progenitor 
cells have differentiated into adipogenic, osteogenic or chondrogenic cell lines, 
transdifferentiation of each committed cell line can occur if the cells are aposed to appropriate 
inductive culture conditions of the other two cell lines. Transdifferentiation into each of the other 
two cell lines was demonstrated through upregulation of mRNA levels of specific factors 
associated with adipogenesis, osteogenesis and chondrogenesis.67 Song and his coworkers67 have 
suggested that his phenomenon may be due to potential progenitor cell contamination from 
possibly multiple stem cells sources within one cell pool or due to cell-to-cell fusion between 
progenitor cells and a tissue-specific cells. Also, the potential ability of cells to reverse to a 
precursor cell stage through dedifferentiation and subsequent redifferentiation into a different 
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lineage has been speculated but requires further investigation. Research is ongoing to 
substantiate the validity of this suggested plasticity of stem cells, defined as “the conversion of 
the cell of one tissue lineage into a cell of an entirely distinct lineage, with the concomitant loss 
of the tissue-specific markers and function of the original cell type and acquisition of markers 
and function of the transdifferentiated cell type”.64,68   
1.1.6 Embryonic versus Adult Stem Cells 
The potential application of stem cells in human tissue engineering has caused 
considerable controversy within the academic, public and political arenas. In the layperson’s 
eyes, stem cells are commonly associated with embryonic origin and thus associated with the 
destruction of human embryos. Therefore, human embryonic stem cell research, under the 
current political atmosphere, is restricted to only a few established cell lines. Embryonic stem 
cells (ES) are believed to have a much longer lifespan compared with the adult stem cell, which 
is directly related to their telomerase activity. Human ES cells have been expanded for up to 250 
population doublings69 (PDs) maintaining their pluripotency and normal karyotype. Therefore, 
these cells are considered more versatile compared with the adult mesenchymal stem cell. 
However, in addition to the ethical issues associated with ES cells, reports that these cells can 
form teratomas in vivo have pushed the emphasis of research more toward postnatally derived 
stem cells. 
Embryonic stem cells are derived70,71 from the inner cell mass (ICM) of the blastocyst 
consisting of an outer cell layer, the trophectoderm, which later develops into the placental 
corion and a fluid-filled blastocoele containing a cluster of cells, called the ICM. It is still not 
clear, however, whether all cells of the ICM are pluripotent and whether ES cells are derived 
from a single or a population of ICM cells within the blastocyst.64 Depending on the species, 
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blastocysts are approximately 1 week-old preimplantation embryos.72-74  The embryonic ICM 
contains pluripotent stem cells (epiblast), which develop into the species-specific organism 
consisting of the three embryonic layers, the endoderm, mesoderm, and ectoderm.68  Embryonic 
stem cells are defined as capable of differentiation into all tissue lineages68 and have much 
longer cell culture longevity compared with adult stem cells, which display replicative 
senescence similar to all other eukaryotic cell lines as stated in the Hayflick limit75, a term that 
was coined by Burnette in recognition of Hayflick’s discovery.76,77 Interestingly, adult cells will 
conform to this predetermined maximum lifespan of approximately 50 cell doublings after 
recovery from a frozen state.78  
The replicative lifespan has been shown to be directly related to telomerase activity, 
which was first sequenced by Blackburn and her coworkers in ciliated protozoa, Tetrahamena 
thermophilia. This discovery allowed length measurements of telomeres, which are the cellular 
replicometer and which are suspected to shorten in aging cells until a critical telomere length 
eventually determines cellular senescence.79 Greider and Blackburn80 discovered telomerase, an 
enzyme that adds telomere repeats to the chromosomes and thereby maintains replicative cell 
activity such as seen in embryonic stem cells68 and cancer cells.81 Telomerase is reduced in 
hemopoietic stem cells (HSC) and variable or even absent in somatic cells.82,83 Embryonic stem 
cells have been reported to survive for 1 to 2 years in culture with cell doubling times of 36 to 48 
hours.73,84,85  Cell aging through serial propagation in culture is related to other degenerative 
changes, which include abnormal cytoplasmic structures, changes in metabolism, loss of methyl 
groups, reiterated DNA sequences, reduction of replicative efficiency and growth rate.86 
Apoptosis and tumorigenicity are possibly associated with a certain genetic instability of these 
aging cells. The putative relationship to cancer has been proposed as signaling pathways, such as 
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those regulated through PTEN, notch, sonic hedgehog and wnt, recently reported for 
hemopoietic stem cells (HSCs)87-92, are also related to oncogenesis.93 ES cells can replicate 
through extended population doublings beyond those manifested for eukaryotic cells. However, 
Deasy and coworkers showed that muscle-derived stem cells (MDSCs) can also be expanded 
over more than 300 PDs during 225 days in cell culture.93 These cells showed normal in vitro 
phenotypic characteristics (ScaI+/CD34+/desminlow) for up to 200 PDs, at which point CD34 
was lost from the surface marker profile concomitant with a loss of muscle regeneration, 
myogenic activity and increased growth on soft agar. These results demonstrate that adult stem 
cells appear to have the ability to replicate long term but that cell aging is inevitable and may be 
related to cancer development.  
1.1.7 Mesenchymal Stromal Cell Frequency 
Pittenger and his coworkers reported MSC frequency in human bone marrow of between 
1 per 104 to 1 per 105 nucleated cells.17  Donor age is a factor influencing human MSC 
frequency.  Their numbers have been reported to decline in an age-related manner from 1 in 
10,000 (newborns) to 1 in 2,000,000 (an 80 year-old person).94 Canine32 and feline95 bone 
marrow-derived MSC frequency has been reported to be 1 in 2.5 x 104 and 1 in 3.8 x 105, 
respectively. Our data show an equine MSC frequency among the total nucleated BM cells of 1 
in 4.2 x 103 (based on CFU-F) in young horses ranging in age from 9 months to 5 years. 
However, MSC frequency in mice96 has shown considerable variation for primary cell 
frequencies (up to ten fold) between individual subjects. Murine bone marrow-derived MSC 
frequency determined from CFU-fibroblasts (F)/- adipocyte (Ad)/-osteoctye (Ob) studies ranged 
between 1 in 10.8 X 103 to 1 in 3.45 X 104.97  One to 2 orders of magnitude differences in 
numbers of bone marrow-derived equine, human17, canine32, feline95 and murine96 MSC 
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frequency may be related to differences in the quantitative methods, age of the donor animals or 
some biological features unique to a particular species. Low plating density and large culture 
volume may influence cell survival relative to microtiter conditions, influencing the detected 
number of MSCs. Age-related correlations in MSC frequency or cell doubling times (2.1 
days/cell doubling) could not be detected from non-hematopoietic bone marrow (nhBM) 
recovered from femoral heads of patients (27-81 years, n = 16) undergoing hip arthroplasty.98 
The authors reported MSC frequencies as high as 1 in 13,000 nucleated cells from these patients.   
1.1.8 Adult Stem Cell Sources 
Adult mesenchymal stromal cells with multipotent differentiation potential can be found 
in many different tissues of the body. It is not clear whether mesenchymal cells are recruited in 
response to natural cell turnover and replenishment or injury from niches in close proximity to 
these sites or from bone marrow. Multipotent cells have been isolated from tissues such as the 
lung99, liver99, kidney99, spleen99, thymus99, placenta100, pancreas101 and even the brain102 and 
nerves58 as well as mesenchymal tissues such as cartilage99,103, muscle60 and adipose tissue17. In 
the horse, bone marrow and adipose tissue are the most useful and accessible sources for MSCs. 
The progenitor cells harvested from these sites in other species have the ability to replicate as 
undifferentiated cells and to differentiate into various mesenchymal phenotypes, including bone, 
cartilage, fat, muscle, tendon and marrow stroma.   
1.1.9 Mesenchymal Stem Cell Niches 
Under in vivo conditions mesenchymal stem cells are believed to multiply and 
differentiate under much more stringent control than their characteristic expansive growth seen 
in cell culture conditions. These multipotent cells are believed to reside in specific niches within 
their respective tissues, which are responsible to both restrain their regenerative capacity and to 
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prevent tumor formation as well as shield them from molecular signals, which could induce their 
cell cycle or differentiation. Hence, these niches provide a balance between the benefit of 
replenishing the demand for mature cell lineages and avoiding the detriment of uncontrolled 
proliferation of progenitor cells.104 
The concept of stem cell niches and their prevailing cellular and molecular mechanisms 
have only very recently been targeted by research efforts. The most well-defined niches thus far 
are those of the hemopoietic stem cell (HSC), the intestinal stem cell (ISC), the hair follicle stem 
cell (HFSC)104 and the neural stem cell niche.105 Cancer development is believed to be associated 
with aberrations in the control of stem cell proliferation in their niches and therefore they provide 
excellent target for therapeutic intervention in cancer treatment.106,107   
Osteoblastic cells provide a niche environment for precursor cells such as the HSC. 
Genetically altered mice produce osteoblast–specific PTH/PTHrP receptors (PPR) and high 
levels of the Notch ligand Jagged-1, which is a HSC growth factor87, which leads to increaseds in 
vivo Notch1 activation in HSCs as well as cultured HSC numbers.108  Parathyroid hormone 
(PTH) activation of PPR caused an increase in cultured osteoblast and HSC numbers, which was 
abolished by γ-secretase, a Notch inhibitor. Furthermore PTH injection increased HSC number 
and survival seen after bone marrow transplantation from the wild-type animals.108 It is believed 
that direct contact between HSCs and N-cadherin+CD45- osteoblastic (SNO) cells lining the 
endosteal bone surface mediate cell proliferation through N-cadherin and beta-catenin molecules 
and through BMP receptor type IA (BMPRIA) controlled signaling of bone morphogenetic 
proteins (BMP) in osteoblastic cells.109  Signaling pathways such as those mediated through Wnt, 
Notch and Hedgehog are also important in regulating HSC growth and proliferation and 
modulation of these transcription factors via the inhibition of glycogen synthase kinase-3 (GSK-
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3) activity have been suggested110, yet are not fully understood.104  Bone marrow contains 
multiple niches for HSCs such as the endosteal and a vascular niche and it has been suggested 
that due to the proximity of stromal stem cells in bone marrow, similar niches are also present for 
the adult mesenchymal stem cell.111 
1.1.10 Stem Cell Phenotyping 
It is important to be able to recognize and identify stem cells based on specific 
phenotypic characteristics in order to define stem cell function and their mechanism of tissue 
repair. In vivo models employed for the study of mesenchymal or hemopoietic cell “stemness” 
allow the localization of these cells based on immunohistochemical detection of stem cell surface 
markers. However, attempts to isolate characteristic cell surface markers of a definitive stem cell 
phenotype from varying tissue sources have thus far been unsuccessful.58,68 Phenotyping these 
cells currently relies on the use of a combination of cell surface markers rather than specific 
surface antigens. There are distinctive differences between the different stem cell types with 
regard to the presence or absence of hematopoietic antigens, CD14, CD34, and CD45 on 
MSCs.17,112 A number of surface markers such as  STRO-1, CD14, CD29, CD 44, CD49a, HOP-
26 (CD63), CD71, CD73, CD90, CD106, CD120a, CD124, and SB-10 (CD166) antigens have 
been described for MSCs.14,17,112-114  Surface markers (CD13, CD29, CD44, CD73 and CD90) 
have also been used to isolate adipose tissue-derived stromal cells.14 In this study primary 
stromal vascular fraction cells expressed these markers to less than 54%, whereas the surface 
marker profile of subcultivated ASCs increased to > 90% of positive cells. These results show 
that the primary nucleated cell pool in stromal vascular fractions derived from adipose tissue and 
the nucleated cell population harvested from bone marrow stroma are heterogeneous in nature 
consisting of varying cell types and stem cells at different stages of differentiation, which may 
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variably restrict their multipotential. Approximately two-thirds of all marrow-derived stromal 
cells show tri-potential when tested under adipogenic, osteogenic and chondrogenic 
conditions.17,98 The remaining portion of the cells were bipotential, capable of adipogenesis and 
osteogenesis, suggesting that these two differentiation processes are more closely related in their 
upstream gene regulation than the control of chondrogenesis. Species-related differences with 
respect to stem cell marker expression and the putative plasticity of stem cells can further 
complicate the identification of stem or lineage committed cells.115  
1.1.11 Effects of Oxygen Tension on Stem Cell Activation 
An important difference between stem cell niches in the body and traditional cell culture 
conditions is the difference in oxygen concentrations. The use of cultured cells in tissue 
engineered constructs or in cell-based approaches introduces a cell previously cultured at 21% 
O2, to hypoxic conditions within the implanted tissue environment. Mesenchymal stromal cells 
undergo significant metabolic changes under such conditions. MSCs live in close proximity and 
metabolic relationship to hematopoietic stem cells suggesting that these cells live in similar bone 
marrow niches.116 This tissue is known to be hypoxic at 1 to 2% O2.117 The proliferative effects 
of hypoxic conditions within bone marrow on HSCs are well known.118  
Oxygen levels are intricately related to self-renewal and differentiation of mesenchymal 
stromal cells. Culturing human MSCs under hypoxic conditions of 2% O2 enhanced proliferation 
of in monolayer culture and within 3D scaffolds. Hypoxia at 2% also reduced differentiation 
processes such as chondrogenesis and osteogenesis whereas at slightly higher oxygen 
concentrations (5%) human adipose-derived stromal cells demonstrated the opposite 
phenomenon of reduced proliferation rates and increased adipogenesis compared with cells 
cultured under traditional 20% O2 conditions. Grayson and coworkers recently showed that 
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hypoxia resulted in approximately 30-fold differences in human MSC expansion rates and 
multilayer cell growth after confluence had been reached in monolayer cultures.119 Hypoxia also 
had a positive effect on mRNA levels of upstream regulators responsible for cell growth, such as 
Oct-4 and HIF-2  as well as extracellular matrix proteins such as collagen I, fibronectin and 
connexin-43, which is involved in gap junction formation.119 Hypoxia (1%) apparently did not 
affect important regulators of adipogenesis such as PPARγ and ADD1/SREBP1c, or downstream 
markers such as lipoprotein lipase and aP2. Yet adipogenesis clearly appeared to be induced and 
enhanced compared with cells grown under 2% and 21% normoxic conditions, as measured by 
lipid droplet and triglyceride accumulation.120 
Hypoxia inducible factors (HIFs) are proteins belonging to the family of bHLH-PAS 
proteins and act as transcription factors responsible for cellular changes in response to hypoxia. 
HIFs bind to hypoxia regulated elements (HRE) at the promoter region of well over 150 target 
genes involved in cell metabolism, survival, motility, basement membrane integrity, 
angiogenesis, hematopoiesis and a number of other functions.121 HIF proteins consist of an α 
(HIF-1α) and β (HIF-1β) subunit. Regulation of HIF activity is largely dependent on the stability 
of its α subunit, which increases under decreasing O2 concentrations.122 The DNA binding and 
transcription depends on the stability of the HIF-α protein, which needs to bind the constitutively 
expressed HIF-β as well as other coactivators such as CBP/p300 within the nucleus at the HRE 
sequence.121  
Differentiation mechanisms appear to be down-regulated by HIF121 as well as Notch.123 
The intracellular domain of Notch is released from the plasma membrane and transported to the 
nucleus after proteolytic cleavage in response to Notch receptor binding with Jagged ligands. 
The recruitment of Notch and binding to a DNA complex with other coactivators (MAML, CSL 
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and p300) leading to downstream activation of target genes such as Hes-1 and Hey-2, requires 
binding of HIF-1.121,124  
The precise interaction between HIFs, Notch and Oct4, which is predominantly 
responsible for regulating ES cell differentiation and the potential interaction with other proteins 
such as BMP and TGFβ is still under investigation. TGF has been shown to induce stability of 
the HIF-1a through inhibition of PDH2, which is a proline hydroxyase targeting degradation of 
the HIF-a subunits under normoxic conditions.125 It appears that low oxygen levels as seen in 
intact tissues such as bone marrow will undermine differentiation processes keeping progenitor 
cells potentially stored in microenvironments and protected from oxidative stresses.  
1.1.12 The Concept of “Stemness” 
The true test of mesenchymal stromal cell “stemness” beyond their ability to differentiate 
in vitro into specific lineages is the demonstration of tissue functionality in animal implantation 
studies and disease models to progress their application in regenerative tissue repair. The ability 
of MSCs to self-renew and expand in culture, to differentiate into different cell lines dependent 
on the appropriate stimuli, and to regenerate tissue only encompasses part of the MSC potential. 
The early experiments in which MSCs were injected into mice under experimental conditions 
resembling osteogenesis imperfecta, demonstrated that the procedure resulted in a small but 
significant increase in bone strength.126 As recently reviewed by Prockop127 similar functional 
improvements were noted in animal models for human diseases such as Parkinson’s disease, 
stroke, myocardial infarction and spinal cord injury. Surprisingly, the clinical effect, which was 
attributable to the cell-based approach, did not appear to be correlated to engraftment or 
differentiation of stem cells. Only few donor MSCs in experiments where human cells were 
implanted into immunodeficient mice after induction of coronary infarction through ligation of 
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the anterior descending coronary artery were found based on sensitive assays of tracing human 
chromosomes in the animal tissues.128 In clinical cases of osteogenesis imperfect, less than 1% of 
donor cells were found within osseous and dermal as well as other tissues.126 These results 
showed that tissue formation alone could not account for the improvement of the clinical or 
experimental conditions, suggesting that MSCs affected the repair process in yet a different 
ways.  
1.1.13 Immunotolerance 
Immunosuppressive effects of MSCs in response to allogeneic transplantation in both 
clinical and experimental models suggest that these cells play an important role in this function. 
The precise mechanisms by which MSCs are tolerated are poorly understood. However, 
experiments show that MSCs can suppress mixed-lymphocyte reactions in culture suggesting 
that MSCs may allow tissue repair following allogeneic bone marrow engraftment by inciting 
immunesuppression.129 Experimental T cells-mediated autoimmune encephalomyelitis (EAE) in 
a murine multiple sclerosis model have shown that the systemic use of MSCs will result in 
drastic improvement of the associated symptoms.130 In a caprine femoropatellar inflammatory 
arthritis model the use of stem cells resulted in lowering the inflammatory response.131  
The mechanisms by which MSCs are believed to avoid allogeneic recognition are partly 
related to cell surface phenotype wherein MSCs are positive for MHC class I, but negative for 
MHC class II, CD40, CD80 and CD86 markers. While the MHC Class I molecules alone can 
incite a T cell response, other surface molecules are required for a secondary response by the T 
cells.132 Therefore, it may be feasible to use MSCs in allogeneic transplantations without 
immunosuppression in the recipient. Also, MSCS are believed to inhibit CD8+ and CD4+ cells 
such as natural killer cells and thereby evade an innate immune response.  Therefore, gene-
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modified MSCs have been proposed as a therapeutic instrument for targeting diseases and 
medical conditions in which MSCs can introduce healing factors or altered genetic sequences to 
replace the body’s own defective codes  “under the radar” of the immune system’s vigilant 
guard. MSCs have been used as carriers for interferon-β delivery to tumors in mice.133 Also, 
gene therapy with genetic codes for vascular endothelial growth factor has been shown to 
improve myocardial function in infracted rats134 135, bone formation through the delivery of 
BMPs136-138 and osteopenia via the delivery of merely a normal collagen type I gene into young 
humans with skeletal malformations due to osteogenesis imperfecta.126,139 
MSCs may be able to provide immune-suppressed microenvironments and therefore 
modulate T cell reactions through the synthesis and release of a multitude of soluble 
factors140,141, prostaglandins and interleukins such as IL-10142 or through direct cell-to-cell 
contact.143 
1.1.14 Mesenchymal Stem Cell Trophism 
MSCs used as feeder cells in co-culture with hematopoietic cells were found to produce 
copious amounts of cytokines and chemokines in culture.144 The patterns of these secreted 
factors changed once the cells were injected into new environments such as the brain, which 
suggested that MSCs promote repair of damaged cells. Hence adult marrow-derived 
Mesenchymal Stem Cells (MSCs) are now known to exert these trophic effects on their 
environment by secretion of a variety of cytokines and growth factors, which act in paracrine and 
autocrine fashion by suppressing the local immune system, inhibiting fibrosis (scar formation) 
and apoptosis, enhancing angiogenesis, and stimulating mitosis and differentiation of other stem 
cells intrinsic to the damaged tissues.145 These trophic effects represent a separate function of 
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stem cells apart from the direct differentiation into committed cell lines required to regenerate 
injured tissue.  
Potapova and coworkers have shown that human MSCs (hMSC) cultured in monolayer or 
as three-dimensional aggregates in hanging drops (spheroids) secreted vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor, angiogenin, procathepsin B, interleukin 
(IL)-11, and bone morphogenic protein 2, which affected endothelial cell migration, extracellular 
matrix invasion, proliferation, and survival in vitro.146 The concentrations of these paracrine 
factors increased 5-20 times in medium conditioned by hMSC spheroid cultures. Differences in 
stimulation of in vitro endothelial cell survival and in vivo umbilical vein endothelial cell 
proliferation, migration, and basement membrane invasion were noticed between media 
conditioned by hMSC spheroids and those conditioned by monolayers of hMSCs.146 Examples of 
the indirect MSC effects on its environment through induction of trophic factors are the release 
of cytokine such as granulocyte colony-stimulating factor (G-CSF), stem cell factor, macrophage 
colony-stimulating factor (M-CSF) and interleukins such as IL-6, which are known supporters of 
hematopoiesis.147 The MSCs are attracted to injured tissue sites by chemoattractant factors such 
as stromal-cell-derived factor 1 (SDF-1), which mobilizes CD117-positive MSCs, or endothelial 
progenitor cells, from the circulatory system to the ischemic and injured tissue such as an 
infracted myocardium.148 The release of G-CSF from MSCs or other inflammatory cells will also 
have a direct mobilizing effect on recruitment of additional MSCs.149 Hence, MSCs are closely 
involved with a multitude of processes, which support different aspects of tissue repair, further 
demonstrating the potential importance of these cells in the tissue repair process via systemic or 




1.1.15 Stem Cell Homing 
One of the important attributes of stem cells, which is still poorly understood, is their 
ability to specifically home onto injured tissues. It is known that adhesion molecules, chemokine 
receptors and their ligands are important for tissue-specific homing of leukocytes as well as 
hemopoietic stem cells. Information is also slowly becoming available regarding the expression 
of these receptors and adhesion molecules in mesenchymal stem cells. Studies that show MSC 
localization predominantly in ischemic injured tissues, such as experimentally-induced 
myocardial infarctions in rats, suggest that MSCs deposited in the left ventricular chamber are 
attracted by and directed to specific receptors and ligands in these injured tissues.150 
Interestingly, this particular study also showed that the infused MSC localization within the 
injured heart soon dissipated (within 4 hours).151 Cells infused intravenously appeared to get 
trapped within the lung parenchyma. This effect can be avoided using vasodilators such as 
sodium nitroprusside.152  
Understanding of MSC homing requires appreciation of MSC expression of chemokines 
(CCR1, CCR2, CCR3, CCR4, CCR7, CCR9, CCR10, CX3CR1, CXCR2, CXCR3, CXCR4, 
CXCR5 , CXCR6)153-158 and their receptors from the different chemokine families, integrin 
molecules such as α1, α2, α3, α4, α5, αv, β1, β3, β4 and other adhesion molecules such as 
VCAM-1, ICAM-1, ICAM-3, ALCAM and endoglin/CD105.151,159,160 These molecules may be 
of specific importance in certain tissues such as the integrin VLA-4 and adhesion molecule 
VCAM-1, which have been found to be crucial in human MSC attachment to the endothelium. 
Considerable variability within the literature regarding the chemokine expression has been 
attributed to the heterogeneity of MSCs and their potential to home toward different tissues.151  
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1.1.16 Mitochondrial Transfer and Stem Cell Fusion 
MSC support in tissue repair was found when MSCs were cocultured with modified 
endothelial cells (A549 ρ0 cells) containing non-functional mitochondria. The coculture resulted 
in colonies of functional A549 cells with MSC mitochondrial DNA but no genomic MSC donor 
DNA.161 The process occurred through a direct exchange of mitochondria or mitochondrial DNA 
between A549 ρ0 cells and MSCs without cell fusion. However, spontaneous fusion has been 
reported between ESCs and co-cultured somatic cells, resulting in a stem cell biomarker 
transfer.162,163 In the context of investigating stem cell plasticity, these studies appeared added 
confusion because in order to determine plasticity between differentiated cell lines robust 
techniques for detection of stem cell fusion are required.164 Reprogramming of somatic cells 
using fusion partners such as embryonic stem cells, embryonic germ cells, embryonal carcinoma 
cells and undifferentiated cells designed to reset gene expression to embryonic state without 
altering the DNA is an emerging tool based on epigenetic mechanisms designed for future cell-
based therapies.164  
1.2 Multipotential and Differentiation Pathways 
After cell culture experiments have established the self-renewal potential of 
mesenchymal stromal cells from varying tissue sources, it is necessary to demonstrate their 
multipotential characteristics by induction of stem cells into adipogenic, osteogenic and 
chondrogenic cell lineages.  
Molecular mechanisms of differentiation have still not been completely elucidated. Baksh 
and her coauthors have recently proposed that adult stem cells undergo differentiation into 
separate compartments, the first of which is governed by transcriptional modification of the 
multipotent MSC without phenotypic change, followed by the second compartment, which is 
24 
 
characterized by phenotypic modification of the precursor cell into a specific cell line.58 
Mesenchymal stromal cells reside within their respective niches and remain quiescent and 
arrested in the G0/G1 stage of the cell cycle until an environmental signal such as a growth 
factor stimulates proliferation and eventually differentiation.58 It is believed that the MSC cell 
devision is asymmetric resulting in two daughter cells, one of which is an exact replica of the 
original cell and the second is a precursor cell that contains a different genetic transcription 
pattern compared with the mother cell. The precursor cell further divides to give rise to bipotent 
and tripotent precursor cells, which morphologically still resemble the multipotent stem cell but 
may then further differentiate into unipotent cells eventually giving rise to varying cellular 
phenotypes such as those osteoblasts, adipocytes, chondrocytes, myocytes or tenocytes. The 
regulation of transitions between the multipotent, partially committed precursor cells and the 
fully committed cells is not completely understood. However, it is known that there is a temporal 
relationship in which cytokine growth factors and extracellular matrix proteins interact with 
multipotent and committed precursor cells. In the search for common control genes between 
differentiation pathways such as osteogenesis, adipogenesis, and chondrogenesis, experiments 
have been conducted to examine expression profiles of 39,000 transcripts that showed at least a 
1.5-fold increase in RNA levels after induction. The results showed that 914, 947 and 52 genes 
are activated during osteogenesis, adipogenesis and chondrogenesis, respectively, whereby 
approximately 25% (235) of the genes upregulated during osteogenesis and adipogenesis are 
common to both differentiation processes as opposed to 10 and 3 between adipogenesis and 
chondrogenesis or chondrogenesis and osteogenesis, respectively.58 A total of 8 genes (period 
homolog1 [PER1], nebulette [NEBL], neuronal adhesion molecule [NRCAM] FK506 binding 
protein 5 [FKBP5], interleukin1 type II receptor [IL1R2] zinc finger protein 145 [ZNF145], 
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tissue inhibitor of MMP4 [TIMP4] and serum amyloid A2) were common to all three 
mesenchymal lineages differentiation processes, suggesting that these genes possibly represented 
a form of master control or were genes responsible for regulation of cellular processes common 
to all three lineages, such as cell adhesion, organization of the actin cytoskeleton and 
inflammatory pathways.58 The relative abundance of common genes during adipogenic and 
osteogenic differentiation suggests that these two processes are more similar and may therefore 
share common precursor cells, compared with the chondrogenic differentiation process. 
1.2.1 Adipogenesis  
Adipose tissue was traditionally considered a storage depot for energy up until the 1980s. 
Since then, however, molecular biological techniques have completely altered our understanding 
of the role of adipose tissue in the body. A variety of gene products were isolated from adipose 
tissue such as adipsin, tumor necrosis factor (TNF)-alpha, plasminogen activator inhibitor-1 as 
well as adipokines such as leptin165 and adiponectin,166 and it was found that these factors were 
regulatory during energy homeostasis under feeding and fasting conditions. Additionally it has 
been shown that adipose tissue is related to insulin sensitivity and obesity, as well as in 
artherogenesis and inflammation.167 Contrary to suggestions of the older literature that 
individuals are born with a set number of adipocytes, it is now believed that based on evidence of 
3H-thymidine incorporation into new adipocytes in rats fed high caloric diets, that adipogenesis 
occurs throughout the life time of an individual or animal and that therefore obesity is governed 
by adipocyte hypertrophy and hyperplasia.168 
Adipogenesis and associated tissue engineering applications are important considerations 
in human medicine due to injuries and diseases such as burns, avulsions, lipodystrophy, post-
surgical defects after breast tumor removal and congenital defects such as Poland syndrome or 
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Romberg’s disease, all of which often cause tissue defects due to absence or loss of adipose 
tissue and therefore significant cosmetic dissatisfaction. Current approaches to correct such 
defects with dermal or free adipose tissue grafts, collagen injections and synthetic materials have 
major disadvantages such as immune reactions, shrinkage, absorption and fibrous tissue and oil 
cyst replacement as in the case of free adipose tissue grafts. The aim is to design soft tissue 
scaffolds which are large enough to provide cosmetic relief to the injured tissues and which can 
integrate into the recipient’s tissue bed thereby replacing the current use of artificial devices such 
breast implants. The engineering is challenging because scaffold size and pore size limit to cell 
seeding and adipocyte growth and expansion.  
Equine veterinary medicine, however, does not currently have much use for such 
cosmetic interventions and therefore it begs the question as to why adipogenesis is an important 
factor to consider in our efforts to study the multipotential of equine stem cells. As previously 
alluded to it is conventionally considered one of the three pillars of differentiation through which 
cells will demonstrate their multipotential capacity. However, it also known that adipogenesis 
and osteogenesis are intimately related to each other and with the more recent discoveries of 
adipokines and their important endocrine functions within the body, adipose tissue has gained 
recognition beyond its functions of energy storage and a physical protection of underlying 
tissues. Therefore, it is important to appreciate the intricacies of adipogenic and osteogenic 
control as it may provide an understanding for future therapeutic interventions in non-union or 
mal-union of bone healing, which is a recognized problem in equine veterinary medicine. 
1.2.1.1 Molecular Control of Adipogenesis 
Adipogenic induction is typically achieved with induction media containing ligands for 
nuclear hormone receptors involved in both adipogenesis and/or osteogenesis, such as 
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dexamethasone for the glucocorticoid receptors or indomethacine and thiazolidinediones for the 
peroxisome proliferator activated receptor (PPARγ). The following is a description of the 
molecular, transcriptional, cellular and hormonal controls known to regulate adipogenesis. 
The very early molecular events determining a primitive mesenchymal precursor cell to 
differentiate into an adipocytic lineage remain unknown. Characteristic for the first stage of fat 
cell differentiation is an initial growth arrest which is then followed by several cell divisions, 
known as clonal expansion.169 During this process the transcription factors peroxisome 
proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein (C/EBPα) are 
expressed, which in turn are associated with a second growth arrest followed by complete 
differentiation. It is believed that PPARγ and C/EBPα have antimitotic properties. The activation 
of PPARγ appears to correlate with the demise of the DNA binding activity of E2F/DP, which is 
an important regulator for many genes associated with cell growth and promoting cell 
division.170  A number of different preadipocytic cell lines such as the 3T3-L1 and 3T3-F442A 
isolated from nonclonal Swiss 3T3 by Green and colleagues171,172 as well as TA1173,174 and 
Ob1771175,176 have been used to conduct studies regarding adipogenesis. These cells are 
indistinguishable from fibroblasts but are already committed to an adipocytic lineage and 
therefore will differentiate readily into mature adipocytes within 4 to 6 days when exposed to 
agents such as cAMP, insulin or glucocorticoids. In 3T3-L1 cells, the transition from a growth-
arrested preadiocyte to a fully differentiated fat cell has been reported in association with a 
PPARγ mediated induction of cyclin-dependent kinase inhibitors such as p18 (INK4c) and p21 
(Waf1/Cip1). C/EBPα has also been associated with the expression of p21. 
 Prior to differentiation into mature fat cells the preadipocytic cell enters a second period 
of growth arrest following clonal expansion. Attempts to define the beginning and the end of the 
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adipogenesis process in culture are difficult, because the process is asynchronous in nature 
occurring progressively in cell clusters making mRNA level expressions patterns difficult to 
determine. However, it appears that adipogenesis is subject to a cascade of events. An early 
biomarkers of the differentiation process is lipoprotein lipase. The appearance of this protein is 
closely followed by a number of transcriptional factors, which result in the expression of the 
mature adipocyte phenotype and the production of a number of adipogenesis end products. These 
include glycerophosphate dehydrogenase, fatty acid synthase, the adipocyte-specific fatty acid 
binding protein (aP2), malic enzyme, the glucose transporter GLUT 4, the insulin receptor and 
considerable triglyceride accumulation.  
1.2.1.2 Transcriptional Control of Adipogenesis 
The key players involved in the transcriptional cascade of adipogenesis are members of 
the CCAAT/enhancer binding protein (C/EBP) family, especially C/EBPα, C/BEPβ, and 
C/EBPδ, the transcription factors peroxisome proliferator-activated receptor-γ (PPARγ). PPARγ 
ligands, such as the thiazolidinedione (TZD) class of anti-diabetic drugs, bind with a range of 
affinities (Kd = 50 – 700 nM). Other ligands such as 15 deoxy-Δ12,14 prostaglandin J2 (15dPGJ2) 
and polyunsaturated fatty acids such as oleate and linoleate177,178 may also bind to PPARγ but 
with much lower affinity (Kd = 2 – 50 μM range). 
The CCAAT/enhancer binding proteins belong to the family of basic leucine zipper class 
of transcription factors and they appear to play a role in both adipogenesis and osteoblast 
development.179,180 These proteins have a profound effect on the fat cell maturation of cultured 
preadipocytic cell lines under adipogenic induction. It is known that mRNA and protein levels of 
CEBPβ and C/EBPδ will rise early during adipogenesis followed by C/EBPα which is induced 
later in the differentiation process, before other end-product genes of fat cells.179 The role of 
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C/EBPs in adipogenesis has been studied with the help of knock out mice181, antisense RNA 
experiments blocking the expression of factors like C/EBPα and embryonic fibroblast models 
lacking C/EBPβ and/or in combination with C/EBPδ.182 
The peroxisome proliferator-activated receptor-γ (PPARγ) is part of a heterodimer 
formed with retinoid X receptor (RXR).179 PPARγ was discovered through cloning specific 
trans-acting factors which bound to the cis-elements (ARE6 and 7 and ARF6) found within the 
enhancer located within the 5’flanking region of aP2. PPARγ governs the function of most 
adipocyte-specific genes and is required for the fat-selective enhancers within the genes 
encoding aP2, lipoprotein lipase (LPL)183 and phosphoenolpyruvate carboxykinase (PEPCK), the 
rate-limiting enzyme of gluconeogenesis.184 In most models of diabetes, gene expression of 
PEPCK is enhanced in the liver and believed to contribute to the increased hepatic glucose 
output.185  
As stated earlier, transcriptional control of adipogenesis follows along a cascade of 
events whereby hormonal cues may initially activate CEBPβ and C/EBPδ, which then activate 
expression of the PPARγ-RXRα complex subsequently causing the activation of C/EBPα. The 
factor ADD1/SREBP1 is also induced during adipogenesis and is regulated in response to 
variations in food intake.186,187 The exact role of is still not completely understood but its 
contribution to adipogenesis in regulating triglyceride and fatty acid metabolism has been 
established. It is considered a weaker stimulus for adipogenesis compared with PPARγ or the 
C/EBP proteins179, yet it is believed that ADD1/SREBP1-expressing cells in conditioned 
medium can activate PPARγ directly or indirectly via promotion of an endogenous PPARγ 
ligand.187 Adipocyte determination and differentiation-dependent factor 1 (ADD1) is a member 
of the basic helix-loop-helix leucine zipper (bHLH-LZ) family of transcription factors that binds 
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to two distinct DNA sequences and has been associated with cholesterol homeostasis, adipocyte 
development, and expression of fatty acid synthase (FAS) and lipoprotein lipase (LPL), two key 
regulators of fatty acid metabolism.186  
1.2.1.3 Cellular and Hormonal Control of Adipogenesis 
Hormonal induction of adipogenesis involves activation of preadipocyte IGF-1 receptors 
(IGFR) by IGF-1 or insulin leading to activation of two separate signal transduction pathways, 
Akt and Ras, which activate adipogenesis via currently unknown effectors. Cyclic AMP (cAMP) 
is induced via methylisobutylxanthine (MIX) contributing to adipogenic differentiation by 
induction of C/EBPβ either via the cAMP element binding protein or other unknown 
mechanisms. Two further adipogenic activation pathways are mediated either through 
glucocorticoids which bind to the glucocorticoid receptor (GR) and thereby resulting in C/EBPδ 
activation and preadipocyte factor (Pref1) repression. Pref1, a preadipocyte cell surface 
glycoprotein, has also been implicated in mediating an antiadipogenic effect of growth hormone 
(GH) in rats.188 A variety of growth factors and cytokines act as inhibitors of adipogenesis 
affecting mitogen-activated protein kinase (MAPK) which phosphorylates PPARγ and its 
heterodimerization partner RXR.  
1.2.2 Osteogenesis 
Work by Pittenger17, Muraglia 189and their coworkers has shown that only about 30% of 
human MSCs have tri-lineage (adipogenesis, osteogenesis, chondrogenesis) differentiation 
potential. The heterogeneity of the differentiation potential was further underlined by the fact 
that the remaining two thirds of the cells were either bipotential, capable of adipogenesis and 
osteogenesis, or unipotent in chondrogenesis.189 These data suggested that there may be a closer 
relationship with regard to the upstream regulatory control genes or even common precursors 
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between adipocytes and osteoblasts compared with chondrocytes.58 With the help of DNA 
microarray technology the profiling of global gene expression has allowed to investigate patterns 
gene activation during the three differentiation processes. It has been shown that among 39,000 
transcripts 914 responded to osteogenesis, 947 to adipogenesis and 52 during chondrogenesis at 
levels of 1.5 or higher compared with controls. A total of 235 genes were shared by osteogenic 
and adipogenic differentiation where as chondrogenesis only shared 3 and 10 genes with 
osteogenic and adipogenic differentiation processes, respectively. Eight genes were upregulated 
during all three differentiation events. These genes included period homolog1 (PER1), nebulette 
(NEBL), neuronal adhesion molecule (NRCAM), FK506 binding protein 5 (FKBP5) interleukin 
1 type II receptor (IL1R2), zinc finger protein 145 (ZNF145) tissue inhibitor of 
metalloproteinase 4 (TIMP4) and serum amyloid A2.58 These genes are known to regulate a 
variety of basic cellular housekeeping processes including cell adhesion, protein folding and 
inflammation rather than representing master control genes.  
The transcription factors regulating adipogenesis have an inverse relationship in the 
control of osteogenesis.167,190,191 Certain conditions that enhance adipogenesis, such as 
glucocorticoid treatment, ovariectomy, immobilization and aging leading to increasing numbers 
of adipocytes and osteopenia.192-195 It has become increasingly more evident during the 1990s 
that mesenchymal stromal cells were able to assume both osteoblastic and adipocytic phenotype 
suggesting possible transdifferentiation mechanisms, which may naturally be related to the 
proximity of marrow adipose tissue and bone.167,196,197 The close but reciprocal balance between 
osteoblastogenesis and adipogenesis has stimulated discussions of how this relationship may be 
used in the future for therapeutic interventions.  
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1.2.2.1 Molecular Control of Osteogenesis 
PPARγ is an important transcription factor involved in osteogenic regulation. The ligands 
for this nuclear hormone receptor are known to inhibit osteogenesis. The importance of the 
PPARγ and its ligands involved in this process is evident from studies in which PPARγ-deficient 
mice spontaneously demonstrated osteogenesis but failed in adipogenesis.198 High affinity 
ligands such as rosiglitazone were able to increase adipogenesis and concurrently reduce bone 
density, whereas osteogenesis seemed to be affected by the low affinity ligand troglitazone.199,200  
Similar to other transcription factors such as Lef1 and Twist, PPARγ binds to the runt homology 
DNA (RDH) binding domain and thereby inhibits the DNA binding site for the runt-related 
transcription factor Runx2/ Cbfa-1 (core binding factor alpha), which is a central regulatory 
protein for osteoblastogenesis.201  
Runx2 expression appears early during embryogenesis within the prechondrocytic 
mesenchyme in two isoforms, the ubiquitous MRIPV Runx2 and the osteoblast-related MASNS 
which later become involved in bone formation. Unlike most other transcription factors, Runx2 
is also expressed in post-mitotic stages of mesenchymal cell division, which is believed to 
augment MSC commitment into and osteogenic phenotype. The differentiation process, requires 
an arrest of the cell cycle, similarly as described above during adipogenesis, and Runx2 is known 
to affect downstream target genes, the CDK inhibitors (CKIs) p21 and p27, which inhibit 
progression into the S-phase. 
Thus Runx2 plays a critical role in determining the fate of cell differentiation during the 
development of bone. It functions as a molecular switch in determining processes of osteogenesis 
and chondrogenesis and is closely intertwined with other regulatory processes such as Wnt/b-
catenin signaling pathway which activate Runx2 in MSCs via the Tcf1/Lef1 regulators to induce 
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osteoblastogenesis.201  Furthermore, Runx2 expression is controlled by down-regulation through 
the Nkx3.2 homeodomain after its induction by BMP2. Both Sox9 (Sry-type high mobility group 
box containing gene 9) and the Nkx3.2 are required for chondrogenesis during the endochondral 
bone formation process.202-205 The control of prechondrogenic expression of Runx2 by Nkzx3.2, 
as well as PTH/PTHrP, is considered a key point in determining chondrogenesis. It is necessary 
to undermine premature bone formation and to allow MSCs commitment into the chondrogenic 
linage.201 In turn, Runx2-dependent activation of vascular endothelial growth factor (VEGF), 
matrix protein collagen type X and the matrix metalloproteinase MMP9 are required for 
endochondral ossification subsequent to the hypertrophic chondrocytes stage during which 
Nkzx3.2 is down-regulated.206,207 CEBP and Runx2 (Cbfa1) also act synergistically to enhance 
osteocalcin (OC) expression. 
1.2.3 Chondrogenesis 
The enormous economic implications and the loss of horses due to osteoarthritic and 
degenerative joint diseases in horses has made chondrogenesis and the cytokines and growth 
factors involved in the differentiation and maturation process of cartilage repair a important 
focus of  equine orthopedic research. As discussed below in the section on cartilage repair in 
horses, it is now generally accepted that certain growth factors such as insulin-like growth factor-
1 (IGF-1) and transforming growth factor-beta1 (TGFβ1) are important substances, which may 
benefit cartilage healing as an exogenous source during the early healing phase, or through 
genetic modification of chondrocytes or progenitor cells. As discussed earlier, stem cells affect 
tissue healing through cytokine release and immunemodulation in addition to tissue regeneration. 
Therefore, these cells are considered an essential for the repair of cartilage. However, there is 
now increasing evidence that mesenchymal stromal cells from varying equine tissue sources are 
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not all created equal. Koerner and coworkers compared bone marrow and peripheral blood 
progenitor cells and reported that only stromal cells derived from bone marrow were capable of 
chondrogenesis in a pellet culture model.208 Giovannini and coworkers, however, showed that 
equine blood-derived fibroblast-like cells do express proteoglycans in pellet cultures and 
concluded that these cells are capable of chondrogenesis yet are inferior to bone marrow-derived 
cells.209 Koch and his coworkers showed that pellet cultures derived from cord blood progenitor 
cells stain for glycosaminoglycans (saffarin O) and showed cartilage morphology with lacunae 
containing chondrocytes.210 Collagen type II expression, however, was not examined in this 
study.  Most recently Kisiday and his coworkers have compared the chondrogenic potential of 
bone marrow and adipose tissue-derived mesenchymal stromal cells in agarose and peptide 
hydrogel cultures with or with out treatment of TGFβ1.211 The results again demonstrate the 
superiority of marrow stromal cells which produced more aggrecan-like proteoglycans under 
both hydrogel culture conditions compared with ASCs. Histological anaylaysis of hydrogel 
cultures containing TGFβ1 for proteoglycan and collagen type II containing matrix as well as 
collagen type II expression evaluated with RT-PCR was only detectable in MSCs but not ASCs.  
Other work has shown that human ASCs cultured with TGFb1, ascorbate and 
dexamethasone have similar biochemical marker profiles to those of articular chondrocytes.212-216 
Awad and coworkers showed that human ASCs appear to demonstrate adequate chondrogenesis 
when cultured on agarose, alginate and gelatin scaffolds despite differences in protein and 
proteoglycan synthesis between the different scaffold cultures.217 Considering the biological (cell 
viability and morphology), biochemical (protein, proteoglycan, glycosaminoglycan and 
hydroxyproline synthesis) and mechanical properties (compressive modulus) the gelatin scaffold 
appeared to perform best overall followed by alginate and the agarose scaffolds.217 More recently 
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Hennig and coworkers compared the chondrogenesis between ASCs and MSCs under the effects 
of BMP6 and TGFβ1.218 It was found that ASCs showed reduced messenger level of BMP-2,-4, 
and -6 and failed to show significant mRNA levels of TGFβ-receptor-I. Accordingly, ASCs did 
not a show significant chondrogenic response when just treated with TGFb1, even at increased 
concentrations of 50ng/ml. The combination of TGFβ1 and BMP6, however, improved the 
chondrogenic capacity by similar levels of gene expression (aggrecan 1 (AGC), collagen alpha 1 
type 2 (Col2A1), and COMP) as those seen for MSCs just under TGFβ stimulus. These results 
confirm earlier work by Im and coworkers who demonstrated inferior matrix production in ASC 
cultures compared with MSCs cultures and further supports the results of Kisiday’s work, which 
also showed nominal responses of ASCs to TGFβ1 compared with MSCs. 
Hegewald219 and coworkers have provided evidence that the joint environment itself is an 
important chondrogenic stimulus to mesenchymal cells within the joint as the synovium is a rich 
source of mesenchymal stromal cells capable of chondrogenesis.220,221 Hegewald’s work has 
shown that hyaluronic acid or autologous joint fluid can induce in vitro chondrogenesis in pellet 
cultures. Proteoglycan expression was increased due to addition of hyaluronic acid or varying 
concentrations of autologous joint fluid, but relatively lower compared with MSC cultures under 
chondrogenic induction with TGFβ1. Immunohistochemistry showed that the addition of 5, 10 or 
50% synovial fluid concentrations to the chondrogenic protocol had significant effects on 
collagen type II expression.219 
The effect of synovial fluid is most likely related to growth factor release from soft 
tissues such as the synovium, the different types of synoviocytes and its progenitor cells. The 
effects of IGF-1222, TGFb1211,222,223, fibro blast growth factor-2 (FGF2)224 on MSCs have been 
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studied by several groups and have all shown to enhance the chondrogenic potential of MSCs or 
even ASCs. 
1.2.4 Current Knowledge about Equine Mesenchymal Stromal Cells 
Equine stem cell biology includes mesenchymal cells from different tissues other than 
bone marrow and adipose tissue. Table 1 summarizes the main findings on all stem cell types 
thus far studied for the horse including adipose- and bone marrow-derived mesenchymal stromal 
cells, embryonic stem cells, and peripheral blood- and cord blood-derived progenitor cells. The 
research efforts on equine ESCs, however, are more comprehensive and therefore deserve a more 
discussion at this point. 
1.2.5 Multipotentiality after Cryopreservation of Stem Cells 
Cryopreservation of stem cells is an essential tool in tissue engineering and deserves a 
brief discussion. The application of cell-based therapies and gene alterations of stem cells to 
increase efficiency and efficacy relies on the complete functionality of these progenitor cells to 
undergo differentiation pathways, release cytokines and regenerate tissues after cryopreservation. 
Cryopreservation causes damage to the cell via extra- and intracellular ice formation, 
dehydration and due to the effects solutions in which the cells are suspended. The rapid rate at 
which cells are frozen is important in order to promote vitrification of the freezing solution rather 
than crystal formation within the cells.225 The process of freezing causes cellular dehydration 
through emigration of water from the cell and intracellular crystallization of water associated 
with mechanical damage due to crushing extracellular ice formation.226 Solute concentrations in 
non-frozen solutions such as high salt solutions are detrimental to the cell because during 
freezing these solutes are excluded from the crystal structure of the ice and thereby cause further 
damage to the cell. Conditions which cause an increase in viscosity, depress freezing 
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temperatures and cause rapid cooling are believed to promote vitrification, a process 
characterized by amorphous ice formation rather than crystalization.225 Prior to cryopreservation 
cells and other small biological tissues are readily penetrated by cryprotectants such as ethylene 
and propylene glycol, glycerol, dimethyl sulfoxide (DMSO) and trehalose. Cells can easily be 
frozen in temperatures of liquid nitrogen of -196°C. Combinations of cryprotectants are less 
toxic and therefore more effective than a single agent.227  
The expansion ability of stem cells after cryopreservation has been documented by Xiang 
and coworkers who cultured cryopreserved mesenchymal stromal cells obtained from bone 
marrow for 15 passages after resuscitation of the cells.228,229 These authors also found that these 
previously frozen MSCs were capable of pluripotent differentiation into mesodermal cell lines 
such as chondrocytes and adipocytes as well as ectodermal neurocytes under the appropriate 
conditions. The identification of the characteristic committed cell phenotype was supported by 
both histochemical analysis of safranin O heterochromia and procollagen type II expression in 
the case of chondrocytes, lipid droplet accumulation for adipocytes and nestin and neuron 
specific endolase RNA expression for neurocytes.228 Human MSCs undergo osteogenic 
differentiation based on evidence of increased alkaline phosphatase expression and nodule 
formation.26 This group also examined the growth kinetics of these cells and found that 
cryopreserved cells showed no significant differences in their self-renewal ability compared with 
fresh cells over the course of 10 passages.26 The post-cropreservation osteogenic potential of 
MSCs is further supported by Yoshikawa and coworkers who implanted cryopreserved cells after 
thawing into hydroxyapatite (HA) constructs and found through histochemical evaluation of in 
vitro culture experiments using plated cells and cells seeded onto HA-blocks as well as after 
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subcutaneous implantation experiments into syngenic rats, that these cells elicited extensive bone 
formation and elevated mRNA levels for alkaline phosphatase and osteocalcin activity.230  
The number of cryopreserved cells appears to have an effect on the post-thaw viability of 
adipose-derived mesenchymal stromal cells.231 It was found that the optimal cell number for 
cryopreservation purposes was approximately 0.5 x 105 cells/ml freezing medium consistent of 
10% DMSO, 10% Ham’s F12 medium and 80% fetal bovine serum. The number of alkaline 
phosphatase expressing cells required increased three-fold after freezing ASCs compared with 
fresh cells. However, this phenomenon was not correlated to colony forming units undergoing 
osteogenesis. More work is yet required in the area of stem cell cryopreservation to optimize post 
thaw cell viability, which is important to obtain the required cell numbers for cell-based 
therapies and implantation techniques in clinical medicine and surgery. 
1.3 Current Status of Stem Cell Biology in Equine Veterinary Medicine  
The treatment of orthopedic injuries and diseases has rapidly advanced in the past twenty 
years with the advent of improved surgical technology, instruments and techniques, such as 
through arthroscopy and new and improved implant materials and designs. However, the horse 
will always be disadvantaged in its ability to heal quickly and efficiently from significant injuries 
such as fractures and tendon and ligament injuries or diseases and developmental conditions such 
as a laminitis and subchondral bone cysts. The reason lies within its significant body weight, the 
resulting forces on soft and hard tissues, and the horse’s inability to psychologically cope with 
ambulatory failure because of its keen fright and flight response. The result of prolonged periods 
of significant lameness or non-weightbearing is all too often the laminitic breakdown within the 
contralateral foot capsule. Therefore, there is a real need to invent and develop new treatment 
techniques which are designed to improve dynamic stability across fracture sites and to increase 
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the speed and efficiency of healing. These will help horses regain ambulatory control and use of 
their injured tissues to avoid further complications and decrease the significant wastage 
particularly common in the competitive equestrian industry.  
Particularly painful and debilitating diseases commonly seen in athletic horses are flexor 
tendonitis and suspensory desmitis. These injuries are distinct from those observed in humans as 
they most often occur as core lesions within the soft tissue rather than complete ruptures such as 
Achilles tendon injuries in human athletes.232 Tendon injuries belong economically to the most 
important orthopedic injuries related to the loss of use of horses from all aspects of an enormous 
equine industry of 9.2 million horses. The equestrian industry contributes $39 billion dollars to 
the yearly US economy of which the racing industry alone is responsible for approximately 
26%.1 The annual incidence of superficial digital flexor tendon injury seen just in Thoroughbred 
race horses ranges from 7 to 43%.233,234 Tendon and ligament injuries are characterized by a slow 
and inadequate healing process, owing to the low metabolic rate of tenocytes, mechanically 
inferior scar tissue formation, and the highly strenuous demands on these soft tissue structures 
during exercise and, especially, competition.  The reinjury rate of SDFT injuries is also high 
ranging from 67% in Thoroughbred race horses due to the high-speed demands to between 20 to 
40% in horses used for show jumping, dressage, polo and other competitive equestrian 
disciplines.  
In recent years, stem cell-based therapeutic approaches have been used in equine 
veterinary medicine to treat the predominantly effected soft tissue structures such as the 
superficial digital flexor tendon (SDFT), deep digital flexor tendon (DDFT), or the suspensory 
ligament (SL) and its branches. Traditionally these injuries have been treated with a myriad of 
therapeutic interventions ranging from blistering and firing tendons to medical and surgical 




treatments. Medical treatments include intralesional or paralesional injections of anti-
inflammatory drugs, tendon matrix constituents or lysyl oxidase inhibitors to prevent collagen 
type 3 cross-linking. Alternative treatments with laser, ultrasonographic, electromagnetic and 
extracorporeal shock wave therapies have also been reported. Surgical approaches such as the 
superior check ligament desmotomy are used in the hope of producing a favorable mechanical 
environment for tendon healing. However, none of these modalities have stood the test of time 
and have often produced questionable results and undesirable consequences. Controlled clinical 
studies are difficult to conduct due to the lack of client compliance, and experimental in vivo 
studies have not provided much more than a 60 – 70 % prognosis of recovery. 
It is generally accepted that intrinsic tendonitis or desmitis, characterized by lesions 
within the core of the tendon or ligaments, particularly affecting the SDFT, is due to injury 
subsequent to repetitive loading and strain. The precise etiopathogenesis and associated 
molecular processes have not yet clearly been defined but are most likely explained by a 
combination of the current multiple theories related to mechanical, molecular, vascular and 
perhaps hyperthermic processes.235 Subclinical and often non-inflammatory events have been 
shown to result in either tenocyte overstimulation or understimulation and subsequent gene 
expression of catabolic factors causing further degeneration.236 Conversely, in clinical tendonitis 
overt inflammation within the lesion secondary to overloading and fibril disruption occur. The 
reason that the aforementioned treatment options do not or only partially address the actual 
problem of the disrupted tissue, is that most of them do very little to regenerate the actual 
structure of the tissue and to prevent the formation of non-elastic scar tissue incompatible with 
its natural function of shock absorption.  
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The notion that transferring bone marrow into injured tendons may be beneficial to the 
healing process within injured tendons was due to the introduction of growth factors and the 
potential of resident mesenchymal stromal cells. The original report described an unusually high 
success rate of 86% within a population of 100 horses.237 Whereas scientifically debatable, this 
report provided important stimulus to further investigate the merit and potential of equine stem 
cells and their combination with growth factors and bioabsorbable scaffolding materials, the 
three pillars of tissue engineering. 
Current cell-based approaches to treating tendon and ligament injuries currently used in 
equine veterinary medicine employ the use of supraphysiological numbers of mesenchymal 
stromal cells either just isolated from adipose tissue (ASC) or isolated and expanded from bone 
marrow (MSC). It is important to recognize the difference between these two approaches, as the 
cells isolated from adipose tissue are a nucleated cell pool referred to as the stromal vascular 
fraction, that contains a relatively high number of mesenchymal cells (~200,000 ASCs/gram of 
fat), but which have not been expanded. MSCs occur in much lower numbers within bone 
marrow and therefore have to be expanded in culture before implantation. Cell culture of MSCs 
for 10 to 14 days, however, will result in much greater cell numbers than the primary ASC 
isolates from the stromal vascular fraction. Hence there are vast differences and variations in the 
applied cell numbers between these two treatment options, which may affect tissue healing. It is 
currently assumed that these high numbers of MSCs and ASCs will regenerate normal tissue 
more effectively compared with the body’s natural ability. Initial reports from clinical data in the 
United Kingdom have shown that the use of bone marrow-derived cells appeared to reduce the 
re-injury rate in both racehorses and sport horses by approximately 20 to 30%, whereby it 
seemed to be important that this therapeutic modality was used early in the course of injury.238,239   
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1.4 Gene Delivery in Mesenchymal Stromal Cells 
Gene therapy involves the insertion of genetic sequences via vectors such as viruses into 
somatic cells, which will change the recipients’ genome but, unlike germline gene therapy, will 
not cause inheritance of the genetic alteration to the next generation. Mesenchymal stromal cells 
are a potential way to introduce genes for the augmentation of cell differentiation and the 
neoformation of tissues. Biologically suitable cell scaffolding and a combination of stem cells 
and gene-enhanced cell differentiation are currently considered the most effective manner of 
tissue engineering. Genetically modified cells have been investigated in a variety of tissues such 
as bone240,241, cartilage242,243, tendons244, brain245 and other nervous tissues246 and the heart247 and 
in diseases such as diabetes248 and cancer control249 through the use of hemopoietic stem cells. In 
equine veterinary medicine, the predominant application of recombinant proteins and gene 
therapy has focused on musculoskeletal diseases such as cartilage resurfacing, fracture healing, 
tendon/ligament repair and wound management. Growth factors of potential clinical relevance 
are those of the bone morphogenic protein family (BMPs), the transforming growth factor-β 
family (TGFβ),  insulin like growth factors (IGFs), platelet derived growth factor (PDGF), 
fibroblast growth factors (FGFs), epidermal growth factors (EGFs) and activins and inhibins.250 
Stewart and co-workers showed that FGF-2 treatment of monolayer marrow-derived MSCs 
resulted in increased mRNA level of collagen type II and aggrecan as well as total 
glycoaminoglaycan and DNA content from pellet cultures under chondrogenic conditions.224 In 
vitro experiments with equine chondrocytes demonstrate that IGF-I appears to have both a 
protective function within the joint as well as a role in supporting extracellular matrix growth. 
The combination of IGF-I and corticosteroids have demonstrated a protective effect on 
proteoglycan degeneration in response to an interleukin (IL)-1 induced inflammatory 
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response.251,252 The anabolic effect of IGF-1 appears to be dose-dependent are related to the 
matrix synthesis by chondrocytes grown in fibrin discs. Proteoglycan content is augmented by 
pretreatment of bone marrow derived MSCs with TGF-β.222,253,254 Equine in vivo models have 
shown that treatment of full-thickness cartilage lesions in the femoropatellar joint with human 
recombinant IGF-I enhanced fibrin clots resulted in improved collagen type II deposition within 
6 months after treatment.255,256  Using scaffolds composed of fibrin and chondrocytes treated 
with IGF-I resulted in superior collagen type II deposition compared with controls not receiving 
IGF-1.133 The exact molecular mechanisms of this anabolic effect remain to be established. 
Messenger RNA levels related to collagen type II and aggrecan expression in cartilage repair do 
not appear to correlate with those of IGF-1.257 
In the equine athlete, cartilage damage is a sequel to the inflammatory events that occur 
in osteoarthritic joints. In osteoarthritis, stem cells are depleted locally, and their proliferation 
and differentiation capacity appears to be reduced.258 This suggest the potential value of stem 
cell delivery into osteoarthritic joints in the hope of reducing the progressive destruction of the 
joint and possibly facilitating repair. Gene enhancement of MSCs in the joint with cartilage 
protective growth factors such as IGF-1 and possibly factors which will reduce the inflammatory 
process within osteoarthitic joints may well further our investigations toward a successful 
treatment for osteoarthritis in the horse and other species. It has been shown in the rabbit model 
that the severe inflammatory and proteoglycan destructive effects of intra-articular injections of 
human recombinant interleukin-1 beta (hrIL-1 beta) was inhibited by the IL-1 receptor antagonist 
(IL-1ra) also referred to as IRAP.259  The use of an adenoviral vector for gene delivery was first 
successful in the laboratory animal model.260 Equine synoviocytes cotransduced with IGF-1 
and/or IL-1ra coding sequences were able to partially or fully reverse the detrimental effects of 
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IL-1 exposure to cartilage explants via AdIGF-I-transduced cultures or AdIGF-I/AdIL-1Ra-
transduced synovial cocultures, respectively.261 The combination of IGF-1 and IL-1ra has 
recently been reported in an elegant study using the same vector model in the horse to treat 
microfractured chondral defects. Iatrogenic defects had filled in after 16 weeks of a controlled 
rehabilitation regime with levels of proteoglycan and collagen type II significantly above those 
of the sham treated controls. Therefore, IL-1ra appears to play a role as a component in the 
treatment of arthritis. Gene therapy via cell transduction with this mediator appears to be a 
suitable method of delivery.  Recombinant IL-1ra proteins are known to have a short half-life of 
4 to 6 hours after intravenous administration in humans, requiring molar IL-1ra/Il-1 ratios of 10 
to 100 to demonstrate efficacy.262 The use of viral particles as reported in the previously 
described study is not suitable for clinical application in animals or humans. The combined 
application of gene encoded IGF-I and IL-1ra may further benefit from transduction into 
mesenchymal stromal cells. Beyond their obvious function as cell and tissue replacement, other 
known advantages such as their cytokine release and anti-inflammatory effects263 are important. 
A recent study in sheep using joint destabilization via medial meniscectomy as a model of 
osteoarthritis showed that MSC-based therapy had a significant effect on articular cartilage 
structure maintenance and the reduction of subchondral sclerosis.131  
Most of the research efforts in regenerative tissue repair for musculoskeletal disease in 
horses thus far have concentrated on cartilage repair and resurfacing due to osteoarthritis and 
trauma induced arthritis, leading to the substantial yearly losses that occur in the competitive 
equestrian industries. In contrast to this body of literature, research into stem cell, scaffolding 
and growth factor or gene-mediated approaches to fracture and subchondral bone cyst repair, 
arthrodesis, and conditions such as malunion or non-union, which are less well described in 
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horses compared with humans, dogs and other species has been limited. Fracture repair in the 
horse is fraught with many possible complications related to the body weight of these animals 
and the susceptibility of laminar tissues in contralateral feet to increased forces during fracture 
healing. Bone regeneration has so far been limited to cancellous bone grafts used during the 
surgical fracture repair or arthrodesis procedures. MSC implantation into mechanically suitable 
scaffolding materials has been investigated in other species for some time. However, due to the 
tremendous body weight of the horse, the majority of the literature on fracture repair has focused 
mostly on internal or external fixation techniques to allow immediate post-operative recovery 
and ambulation on the affected limb. Most scaffolding materials required to fill large fracture 
defects are not yet sufficiently strong or have not been tested under the conditions a horse would 
impose. However, recent studies in sheep using autologous MSCs seeded onto porous 
hydroxyapatite ceramic have been encouraging but will require validation of mechanical 
suitability before this material is used in the equine model.264  
A recent study using equine MSCs has shown that adenoviral vector transduction of 
BMP-2 and BMP-6 resulted in significant upregulation of these two osteogenic factors under 
appropriate osteogenic induction.241 The use of a gene-mediated approach showed accelerated 
differentiation and ossification of monolayer cultured cells as well as transduced MSCs seeded in 
three-dimensional alginate culture systems for both cytokines. BMP-2 transduced cells showed a 
very sharp increase (2514-fold) in BMP2 expression during the first 48 hours and subsequently 
leveled off after 12 days (20-fold), whereas RNA levels of BMP-6 rose sharply by 2 days (6236-
fold) after induction but only reduced 10-fold over the course of three weeks, suggesting that 
there is a time-dependent role for both of these genes in osteogenesis. Equine-specific microarray 
analysis showed that a number of other genes, such as those related to inflammation (IL8, 
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CXCL2), osteogenesis (cartilage oligomeric matrix protein [COMP], procollagen α 1, BMP6 
precursor, SMAD6, procollagen α-1 type III precursor (COL3A1), parathyroid hormone-related 
peptide) and cell differentiation (inhibin β A subunit, keratinocyte growth factor [fgf-7], fibulin-
1 [FBLN1], and retinoid acid receptor responder [RARRES1]) were upregulated in response to 
BMP induction. Genes commonly related to tissue repair, which did not appear to be affected by 
BMP-2 or -6 were aggrecan core protein, biglycan, decorin, dermantan sulfate proteoglycan, 
fibronectin, insulin-like growth factor II, SOX-9, collagen type II.241 
A number of other growth factors may soon be used for genetic enhancement of 
mesenchymal stromal cells in the attempt to optimize regenerative tissue repair. Some of the 
growth factors which have gained increasing attention for their application for equine 
musculoskeletal diseases are the platelet derived growth factor (PDGF) and TGF-β. These 
growth factors can be derived from autologous platelet concentrates deposited in injured tissues. 
These are presumed to benefit the healing process through degranulation and release of PDFG 
and vascular endothelial growth factor. These factors appear to augment neovascularization, 
through stimulation of endothelial cells and TGF-β, which is known to stimulate mitosis and 
differentiation in osteoblastic progenitor cells and subsequently osteoid production.250  Increased 
concentrations of PDGF and TGF-β have recently been reported in a study, which showed that 
PRP has anabolic effects on explants of the equine superficial digital flexor tendon (SDFT). This 
was determined by quantitative RT-PCR of collagen type I (COL1A1), and III (COL3A1) and 
COMP mRNA levels, and it was also found that PRP does not activate catabolic factors such as 
MMP-3 and MMP-13.265 Interestingly, acellular bone marrow appears to have even greater 
effects on COMP and total protein synthesis of equine suspensory fibroblast cultures compared 
with PRP and equine serum.266 Bone marrow supernatant has mostly anabolic effects but factors 
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such as age may change the profile of the protein composition in acellular bone marrow as a thus 
far unidentified protein in bone marrow supernatant has been reported to have inhibitory effects 
on osteoblast proliferation in aging rats.267  The promotive effect of platelet-rich plasma derived 
growth factors on differentiation and tissue regeneration in wound healing involves thrombin 
activation, platelet degranulation and growth factor release leading to improved epithelial 
differentiation and improved collagen bundle organization.268 Platelet-rich plasma enhances bone 
healing in defects around canine dental implants.269  
1.4.1 Cartilage Repair 
Cartilage degeneration associated with osteoarthritis is one of the major orthopedic 
concerns in both human and veterinary medicine. Hence, cartilage repair has been investigated 
for many years with promising advances in scaffold material development as well as growth 
factor and cell integration. A cartilage repair protocol as reviewed recently by Caplan5 consists 
of expanding MSCs collected from bone marrow in monolayer culture before seeding upon 
fibronectin-coated hydroxyapatite (HA) sponges. The high-molecular weight HA has been found 
to be chondroinductive270,271 and anti-angiogenic. Studies using MSCs in implanted vascular-
excluded porous CaP ceramic vehicles have shown that an avascular microenviroment 
encourages MSCs to form cartilage. Furthermore the oligomers of the degraded HA scaffold 
trigger the neovascularization of hypertrophic cartilage followed by replacement with 
vascularized bone and the integration of the neocartilage with the host cartilage.272-274 
The use of growth factors such as insulin like growth factor-1 (IGF-I) integrated into a 
fibrin base to recruit stem cells from within the cartilage and the deeper layers of an equine 
femoral trochlear ridge cartilage defect model has been examined showing that.275 Also, 
chondrocyte and MSC integration into a fibrin base has been investigated and the results have 
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shown that the fibrin glue itself improved collagen type II concentration (expressed as a 
percentage of collagen type I) in the repair tissue from 27% to 43% when compared with defects 
that were not filled with fibrin. However, adding IGF-I to the fibrin clot further improved 
collagen type II expression to 47%, which was found to be significantly different from just using 
the fibrin scaffold without the growth factor. However, adding autologous chondrocytes into to 
the fibrin base yielded the best results showing a collagen type II expression of 62%.276 
Adenovirus transduction of IGF-1 into chondrocytes has shown to improve healing during the 
first 1 to 2 months after injury whereas less benefits were seen after long term-follow-up of the 
injury.277 Similar results of an early response in cartilage were also seen when MSCs implanted 
into experimental cartilage defects in equine femoropatellar joints.278  These results suggest that 
IGF-1 and genetic modification of chondrocytes with IGF-1 as well as MSC implantation have 
positive effects on cartilage healing. Further work using other combinations of other scaffolds 
such PRP (platelet rich plasma) and stem cells programmed by growth factors and gene 
modulations to differentiate into chondrocytes is on the way and has recently been introduced at 
the annual ACVS Symposium. 
1.4.2 Tendon/Ligament Repair 
Equine tendon and ligament injuries are the second most important orthopedic condition 
in equine athletes and hence revenue in the competitive equestrian industry every year. The use 
of stem cells for tendon repair in horses, however, has been limited to cell replacement therapy 
since to date stem cells or bone marrow aspirates have merely been injected without an 
additional matrix. Growth factors such as IGF-I, have been used along with stem cells to enhance 
collagen type I expression. The use of this growth factor in collagenase-induced lesions has 
shown that tendons treated with IGF-I expressed increase Cell proliferation and collagen content 
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and there was overall less soft tissue swelling in the treated tendons as compared with saline 
treated tendon controls.279 A separate study examining the temporal expression of IGF-I and 
transforming growth factor-β1 (TGF-β1), and extracellular matrix proteins collagen type I and 
III found that TGF-beta1 expression occurred within 1 week of the would healing process and 
therefore much earlier than IGF-I, which peaked 4 weeks after the injury and remained elevated 
until week 8.279 Messenger RNA levels of both collagen types remained high for 8 weeks after 
reaching their peak within the first 7 days. The conclusion of these studies was that IGF-I is an 
important factor in the tendon healing process and that early exogenous IGF-1 administration 
may benefit tendon healing by elevating low endogenous levels of the growth factor during the 
first four weeks after the injury.  
So far no adequate scaffolds have been added into core lesions of tendons along with 
stem cells. The only exception is a product with the somewhat misleading name of ACell, Inc. 
(www.acell.com), which is an injectable product and does not contain any stem cells. It is a 
lyophilized acellular powder, which is derived from extracellular urinary bladder matrix (UMB) 
of specific pathogen free (SPF) pigs. ACell has had mixed anecdotal success and after a period 
of legal disputes about proprietary rights their products are once again commercially available on 
the market again. The only peer-reviewed paper reports that 84.4% of 77 horses with 
proximal/body suspensory ligament lesions, 86.7% of 15 horses with suspensory branch lesions 
and 92.9% of 14 animals with superficial digital flexor tendon were found to be sound and 
returned to work within 12 months or more after treatment.280  Ultrasonographic examination of 
the lesions revealed considerable fluid infiltration at 5 and 30 days post injection but had 
improved fiber pattern and minimal edema formation by Day 60.  
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The use of stem cells for equine tendon and ligament strain injuries was established 
during the mid 1990s in the form of bone marrow transfers from the sternum directly into the 
tendon lesion. A retrospective study by Herthel237 reported an 86% success rate of horses 
returning to work after 6 months. This report suffered from a lack of classification of tendon 
lesions, breed heterogeneity and use of the treated equine population as well as a lack of 
appropriate follow-up data. The results, however, appeared to provide an impetus in the equine 
research community and commercial market. Stem cells are now commercially available for 
horses from two different companies. Some companies (VetStem, Inc., Poway, CA, USA; 
Evostem Finland Ltd, Kangasala, Finland) isolate autologous stem cells from adipose tissues and 
VetStem Inc. has more recently also advertised their services for canine tendon injuries 
commonly observed in the dog racing industry. Other companies (VetCell BioScience Limited, 
London, United Kingdom) provide autologous stem cell isolates from bone marrow. Since 2002, 
the American and British stem cell companies report that between 400 to 600 horses have been 
treated and claim approximately 70% prognosis for racehorses to return to racing.281 However, 
no controlled studies have so far been undertaken to show the efficacy of these cells to improve 
tendon healing. A common measure of a successful tendon repair is if a horse is able to race 
three or more times without reinjury and such data are still lacking.  
Surgical implants based on collagen-suture scaffolds seeded with mesenchymal cells 
have not yet been employed for tendon lacerations exhibiting partial or complete transsection in 
horses. However, in rodent models these scaffolds have been successfully used. The constructs 
are designed by aligning a suture material under tension within a collagen scaffold and then 
seeding the collagen with mesenchymal cells. The transplanted cells will orientate themselves 
along the suture material and begin to contract the collagen. Such constructs were used in a 
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rabbit Achilles tendon repair model by Young and coworkers282 which resulted in significant 
improvement in morphological, structural, material and mechanical properties compared with 
simply reapposing the transected tendon with suture material. The inserted constructs improved 
cellular alignment and elongation as well as improved fiber bundle thickness and crimp 
parameters of the repaired tendon segment.  
Synthesis of the first in vitro engineered tendon based on rat Achilles tendon cells which 
were first grown to confluence in monolayer culture and later allowed to self-assembly within a 
cylinder between two anchor points.283 The resultant scaffold free tissue was composed of 
aligned small diameter collagen fibrils and a large number of cells as well as an excess of non-
collagenous extracellular matrix and showed structural, morphological and also mechanical 
characteristics similar to that of chick embryo tendons. 
The search for a mechanically optimal scaffold or engineered tendon implants is ongoing. 
Further research is still required to elucidate the tenocytic potential of MSCs and ASCs, the role 
of mechanical forces on mesenchymal stem cell differentiation, and the impact of growth factors 
and other mediators as well as the cell to matrix interaction to optimize the results of scaffold 
development is required. 
1.4.3 Bone Repair 
Bone marrow transplants provide an osteoinductive and osteoconductive environment for 
resident stem cells and have been used in horses to augment repair of bone fractures and joint 
arthrodesis procedures.284 While the use of MSCs in bone repair has been extensively 
investigated in other species, applications of MSCs for the repair of larger equine fractures have 
been hampered by the lack of suitable scaffolding materials. Such materials require a number of 
other parameters, the most important of which is that the material is mechanically sensitive to the 
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site providing sufficient compressive strength to withstand the rigorous biomechanical demands 
of an adult horse. Furthermore, the material has to be porous in nature to allow or encourage cell 
attachment and access to bioreactive materials aimed to encourage cellular proliferation and 
differentiation. Since most scaffolding materials will have different mechanical properties than 
the host tissue, they will either need to be incorporated into the tissue or facilitate bioabsorption.  
Such scaffolding materials does not yet exist which will continue to limit effective bone 
repair in equine orthopedic surgery. Stem cells and appropriately sized scaffolding materials 
would be most beneficial in the repair of large bone defects in fractured equine long bones. 
Fracture repair in horses is subject to tremendous mechanical challenges and possible 
complications, unlike those that occur in any other species in which osteosynthesis and fracture 
repair is commonly performed. The horse’s post-operative survival is largely dependent on its 
ability to bear weight on the repaired leg during and immediately after recovery from surgical 
correction of a fracture. Therefore, fractures with large bone defects are very instable and despite 
internal fixation and coaptive cast stabilization will bear a guarded to poor prognosis.  
Bone marrow biopsies harvested intra-operatively from the tuber coxae and less 
frequently from the sternum or the proximal medial tibia have been used to augment 
osteogenesis, osteoinduction, osteoconduction and osteopromotion for orthopedic procedures 
such as fracture repair and arthrodesis techniques. Bone marrow biopsy tissue lacks mechanical 
stability and has a relatively low number of progenitor cells per unit weight of tissue, which 
limits the use and versatility of this technique. Their use in cystic lesions such as the common 
medial femoral subchondral bone cyst in young horses has been met with limited success due to 
bone marrow necrosis after implantation into the lesion. Therefore, the rate-limiting step in the 
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tissue engineering for equine fracture repair will be the design of new implant materials with the 
appropriate mechanical properties. 
1.5 Other Potential Applications of Stem Cells in Equine Veterinary Medicine  
Other potential applications for stem cells in equine veterinary medicine including 
traumatic and degenerative skeletal condition such as arthrodesis, mal- and non-union during 
fracture healing, degenerative joint disease (DJD), dermal injuries, wound management and 
vascular diseases such as equine laminitis and ischemia reperfusion injuries after intestinal 
insults. While the treatment of intestinal distension-related ischemia reperfusion injuries with 
stem cells is still only conceptual, another very significant vascular disease of the horse, 
laminitis, has recently received increasing attention. 
1.5.1 Equine Laminitis and the Equine Metabolic Syndrome 
Acute laminitis is a debilitating, painful, and potentially career-ending and life-
threatening disease of the soft tissues (laminae) of the equine digit. At the pathological level, 
laminitis reflects an induced vascular dysfunction afflicting the vasculature of the hoof, which 
leads to laminar edema formation, tissue ischemia, activation of additional systemic or local 
inflammatory mediators, and enzymatic abnormalities. The ultimate result of these processes is 
laminar tissue injury/necrosis, lameness and eventually mechanical failure with rotation or 
sinking of the distal phalanx within the hoof capsule. In other words, laminitis destroys the 
tissues responsible for supporting the horse by suspension of the distal phalanx within the hoof 
capsule. 
Laminitis causes high morbidity and mortality for the horse and leads to economic and 
emotional costs for the owners. Approximately 15% of horses in the US are afflicted with 
laminitis in their life, and 75% of these develop lameness and debilitation necessitating 
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euthanasia. Monetary losses associated with equine laminitis are estimated at $13 million per 
year associated with diagnosis, treatment and animal loss due to complications.  This, combined 
with an incomplete understanding of the disease, helps explain why 3,500 equine veterinarians 
responding to the American Association of Equine Practitioners (AAEP)-sponsored survey 
considered it the most important equine disease and the number one area for future research 
(http://www.aaep.org/).  
The pathogenesis of laminitis is not fully understood; however, there are a number of 
pathological and experimental observations that link this equine disease to human conditions 
such as diabetes and Raynaud’s syndrome.285-287  Inactive horses often develop visceral obesity 
and subsequently exhibit a “metabolic syndrome” characterized by insulin resistance, glucose 
intolerance, hyperlipidemia, and hypertension, a spectrum resembling human type 2 diabetes 
mellitus.  The onset of acute laminitis routinely precedes the diagnosis of the equine metabolic 
syndrome since the metabolic syndrome often goes unnoticed.287  Horses afflicted with laminitis 
frequently display a peripheral Cushing-like disorder characterized by elevated levels of serum 
glucocorticoid and increased steroid converting enzyme (11β-hydroxysteroid dehydrogenase-1) 
activity within the laminar tissues.288-290  In man, clinical investigators have postulated that 
localized conversion of glucocorticoids by 11β-hydroxysteroid dehydrogenase-1 in adipose 
tissue promotes the onset of metabolic syndrome and type 2 diabetes mellitus.291,292  
Overexpression of this enzyme in adipose tissue of transgenic mice produces all of the 
physiologic changes expected in metabolic syndrome.291  In vitro studies have determined that 
the pathological tissue changes occurring in laminitis result from glucose deprivation and 
associated matrix metalloproteinase activation.293  Likewise, in vitro analyses have demonstrated 
that equine endothelial cell function is inhibited by homocysteine, a risk factor in man for 
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atherosclerosis and small vessel disease.294,295 In summary, equine laminitis represents a small 
vessel dysfunction directly associated with a human-like “metabolic syndrome”.   
Some of the benefits of adult stem cell application is apparent from studies which have 
shown that MSCs from humans296 and rodents297 may readily differentiate into endothelial cells 
and are capable of expressing potent angiogenic growth factors298. Arterial infusion of adult bone 
marrow-derived stem cell populations has been shown to protect humans299 and rodents300-302 
from the necrotic consequences of prolonged vascular ischemia/reperfusion of the hind limb. 
These findings support the potential value of adult bone marrow stem cells for the treatment of 
horses suffering from acute ischemic injury associated with laminitis. 
A number of animal species are used as surrogate models for small vessel disease in man, 
including the mouse, rat, dog, and pig.  Each of these animals offers certain advantages.  Rodents 
provide inbred, genetically defined animals available in large numbers at relatively low cost.  
The dog and pig, with their larger body mass, provide a vasculature more closely approximating 
that of humans.  However, large animals such as the horse are rarely used as a preclinical model 
due to its cost and the lack of suitable research facilities accommodating its use in most major 
medical centers.  Nevertheless, horses suffer from diseases relevant to the human condition and 
thereby offer a unique opportunity as an experimental model.  With its greater size and weight-
bearing loads, the demands placed on small vessels in the equine model are expected to meet or 
exceed those required in man.  Thus, this offers the unique possibility to test the safety and 
efficacy of an adult stem cell therapeutic in a clinical veterinary setting.  The outcome of in vivo 
experimental trials will have direct commercial application in veterinary medicine and will 




Equine stem cell biology is just now beginning to blossom and benefits from all the work 
that has already been performed in other species. The horse is a unique model as it is the most 
athletic domestic animal of all that are likely to receive the benefit of technical advances in 
regenerative tissue repair. Most of the diseases currently under investigation in the horse are of 
an orthopedic nature, for which cell-based therapy may prove to be useful in augmenting 
osteosynthesis for equine fractures, arthrodesis procedures and subchondral bone cysts, tendon 
and ligament repair and cartilage resurfacing. However, the horse’s bodyweight and its 
unparalleled impressive athletic ability pose the most challenging constraints for tissue 
engineering and it is postulated that advances in this species will inevitably translate to 
successful therapeutic results in other species such the human and the dog. Therefore, it is 
important to strike the delicate balance between the four different constituents of successfully 
engineering or supporting the repair of new tissues in the injured equine athlete. Current efforts 
are directed toward establishing the basic understanding of the frequency and growth 
characteristics of stem cells from varying tissues in culture in order to amplify their numbers 
required for tissue engineering. Furthermore it is important to demonstrate the in vitro 
multipotential differentiation capacity of equine stem cells before these cells are then further 
tested for functionality in the tissues of interest.  
The natural environment of stem cells provides a mixture of cell-to-cell and cell-to-
matrix cues and these progenitor cells require anabolic factors, an appropriate inductive and 
conductive matrix as well as mechanical stimulation to facilitate tissue alignment and maturation 
during the healing phase. However, unlike bone, some other specific tissue such as tendons and 
ligaments are not capable of providing a sufficient balance of these required factors resulting in 
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production of inferior scar tissue predisposing to reinjury in 58% of injured racehorses. Isolation 
of progenitor cell populations from adult horses has so far been unsuccessful.303 Mesenchymal 
stromal cells isolated from fetal tissues and young horses are believed to reside in the endotenon 
adjacent to the vasculature and in-between collagen fascicles, have demonstrated inferior 
multipotential compared with that recognized in bone marrow-derived MSCs. Therefore, it is 
likely that tendons and ligaments may obtain their requirement for stem cells after injury from a 
peripheral blood-derived or adjacent marrow-derived pool of progenitor cells. Current cell-based 
techniques have been aimed at using supraphysiogical numbers of MSCs or ASCs. Prospective 
studies using MSCs report lower tendon reinjury rates238,239 and ASCs also appear to benefit the 
tissue organization after collagenase induced injury.304  
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CHAPTER 2.  
CELL GROWTH CHARACTERISTICS AND DIFFERENTIATION FREQUENCY OF 
ADHERENT EQUINE BONE MARROW–DERIVED MESENCHYMAL STROMAL 
















The postnatal bone marrow contains marrow stromal cells, also known as mesenchymal 
stromal1 or stem cells (MSCs).2,3 These cells have the ability to differentiate along multiple 
lineage pathways in vitro as summarized in recent reviews on stem cell characterization and 
clinical application in human2-7 and veterinary medicine8.  Since MSC-based therapeutic 
approaches have been investigated for some time in human medicine and surgery, veterinarians 
are now considering equine bone marrow-derived MSCs as potential therapeutic agents for 
musculoskeletal problems such as tendonitis,  desmitis9, as well as bone and joint10-related 
conditions in the equine athlete. Recent in vivo studies using a rabbit model have shown that 
MSCs can contribute to improved biomechanical characteristics following tendon repair.11,12 
Multiple studies document the need for sufficient numbers of MSCs in order to optimize 
musculoskeletal tissue repair.3,5,8,13,14 It has been calculated that 70 million progenitor cells are 
required to produce a cubic centimeter of bone.15 Cell-based approaches to tendon and ligament 
injury repair have employed supra-physiologic numbers of MSCs.9,16 Awad and coworkers, 
using a rabbit model, found that greater MSC seeding densities affected cellular morphology and 
contraction kinetics in collagen scaffolds.17  Therefore, in order to generate the requisite number 
of cells required for tendon and ligament repair, it is necessary to characterize the growth 
characteristics of equine MSCs. 
The majority of the published work documenting MSC differentiation potential, however, 
has been performed in species18 other than the horse, with the exception of the ability of equine 
MSCs to undergo chondrogenesis.19.  Likewise, cell quantification and expansion data of bone 
marrow-derived MSCs have been reported for humans20,21, dogs22, sheep23, rats24, cats25 and 
Rhesus Macaques26 but not in the horse.  
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Therefore, the objectives of this study were to document and quantify the growth and 
differentiation characteristics of equine bone marrow derived MSCs using limit dilution assays 
for adipocytes, alkaline phosphatase positive cells, fibroblasts, and osteoblasts.  This data will 
assist future efforts to standardize the isolation, expansion, and transplantation of equine MSCs 
in clinical practice. 
2.2 Materials and Methods 
2.2.1 Materials 
All chemical reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA) or 
Fisher Scientific International Inc. (Hampton, NH, USA) unless otherwise noted. 
2.2.2 Animals and Signalment 
Bone marrow (BM) was collected from the sternebrae of 5 horses ranging in age from 9 
months to 5 years (mean ± SD: 2.4 ± 1.7 years) and 3 pony foals ranging in age from 17 to 51 
days of age. All horses were Thoroughbreds, except for one 5-year-old Quarter horse. The bone 
marrow collection procedure was approved by the Institutional Animal Care and Use Committee.  
2.2.3 Bone Marrow Aspiration and MSC Isolation 
The methods used for bone marrow aspiration27 and MSC isolation16,19 are similar to 
other reports.  Briefly, young horses were selected from the research herd and after sedation with 
detomidine HCl (Domosedan® 0.04 mg/kg IV). The sternebrae were aseptically prepared and 
local anesthetic (2% Lidocaine, 3 ml) was infiltrated into the subcutaneous tissue. A 40-ml 
volume of bone marrow aspirate was collected using a 10-gauge, 3-inch bone marrow biopsy 
needles and heparinized syringes (1,000 IU/ 10ml BM aspirate). Bone marrow was also 
harvested from foals by sterile curettage of the sternebrae from fresh cadavers. The marrow 
trabecular bone was then crushed and gently stirred before marrow stromal cell (MSC) isolation 
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and expansion, which was performed immediately after the bone marrow collection for all 
animals.  
The bone marrow aspirate was diluted in a 1:3 ratio with stromal medium consisting of 
DMEM-Ham’s F12 medium (vol/vol, 1:1) (HyClone, Logan, UT, USA), supplemented with a 
1% antibiotic/antimycotic solution (MP Biomedicals, Irvine, CA, USA) and 10% characterized 
fetal bovine serum (FBS, HyClone) and layered over Ficoll-Paque® PLUS (Stem Cell 
Technologies, Vancouver, BC, Canada). The nucleated cells of the BM aspirate were 
fractionated over a Ficoll density gradient by centrifugation at 1400 rpm for 30 minutes at 4°C. 
The MSC-enriched cell population above the Ficoll layer was then aspirated and washed in 
calcium and magnesium-free Dulbecco’s balanced salt solution (CMF-DBSS) by further 
centrifugation at 1,200 rpm for 5 minutes at 4°C. The washed pellet was resuspended in 10 ml of 
stromal culture medium. Subsequently, a small aliquot of the cell suspension was centrifuged, 
the supernatant removed and the pellet was resuspended in an equal volume of a red cell lysing 
buffer for approximately 20 minutes (Sigma-Aldrich Co., St Louis, MO, USA). This extended 
exposure period resulted in lysis of both erythrocytes and nucleated cells.  Subsequent trypan 
blue exclusion and hemocytometer counting was employed to determine the total number of 
nucleated cells per unit volume of bone marrow aspirate.  
2.2.4 Cell Doubling Method 
Primary cells from the subjects were plated at a density of 105 nucleated cells per cm2 in 
T25 culture flasks (Corning®, NY, USA) using the above described stromal culture medium. 
The cells were incubated for 6 days before the first medium change, allowing MSC adherence 
and facilitating removal of the nonadherent hemopoietic cell fraction. Thereafter, the medium 
was changed every 3–4 days until the adherent cell population reached approximately 80% 
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confluence. At this point, the adherent primary MSCs were passaged by digestion with 0.05% 
trypsin, counted with a hemocytometer, and a portion of the cells were re-seeded as “Passage 1” 
(P1) at 5 x 103 MSCs/cm2. For the subsequent passages (P1 to P10) cells were inoculated in T25 
flasks at 5 x 103 MSCs/cm2and allowed to multiply for 3 to 4 days to approximately 70 to 80% 
confluence before trypsinization and successive passage.  Cell doubling times (DT) and numbers 
(CD) were calculated from hemocytometer counts and cell culture time (CT) for each passage 
according to the following two formulae28: 
(1)   ( ) ( )2lnln if NNCD =  
(2)   CDCTDT =  
 (DT = cell doubling time; CT = cell culture time; CD = cell doubling number; Nf = final 
number of cells; Ni = initial number of cells) 
All primary cells of the three foals were trypsinized and cryopreserved after they had 
reached approximately 80% confluence at P0. The cryopreservation medium contained 80% fetal 
calf serum, 10% DMEM, and 10% dimethyl sulfoxide (DMSO.  Cryovials containing the MSCs 
were placed in a 5100 Cryo 1°C Freezing Container (Wessington Cryogenics, UK) for 24 hours 
at -80°C before transfer to liquid nitrogen. The MSCs from the three foals, used only for cell 
doubling experiments, were thawed at room temperature, counted with a hemocytometer to 
assess viability, and subsequently centrifuged at 1,200 rpm for 5 minutes before resuspension in 
stromal medium. The cells were then seeded for P1 at 5 x 103 cells/cm2.  
The MSCs isolated from the five adult horses were used only as freshly harvested cells 
that had not been cryopreserved. Cell cultures from each of the five horses were grown in 
duplicate for each passage, whereas those of the three foals were only gown as single cultures.  
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2.2.5 Colony Forming Unit (CFU) Assays 
 The CFU limit dilution assays were performed according to previously 
published methods.29  A portion of  the original isolated bone marrow nucleated cell pool from 
the five adult horses was reserved for limit dilution assays to quantify colony forming units for 
fibroblasts (CFU-F), and cells capable of differentiation into adipocytes (CFU-Ad) and 
osteoblasts (CFU-Ob). Further CFU assays were performed at passage 2 (P2) and 4 (P4). 
Medium exchanges were performed every two to three days. Digital images were taken with an 
inverted phase contrast microscope at each passage and evaluated for cell morphology, 
distribution and confluence.  
Primary cells were seeded and serially diluted (2-fold) across the 12 columns of four 96-
well plates resulting in one plate for each CFU assay (CFU-F, CFU-Ad, CFU-Ob). Due to the 
anticipated low frequency of primary MSCs in P0, the nucleated bone marrow-derived cell pool 
was plated at greater per well densities relative to P2 and P4.30 Hence primary cells densities 
plated in 100 μL of stromal medium per well in each column were 1 x 105, 5 x 104, 2.5 x 104, 
1.25 x 104, 6.25 x 103, 3.12 x 103, 1.56 x 103, 7.8 x 102, 3.9 x 102, 1.95 x 102, 9.76 x 101 and 4.88 
x 101, respectively. The cells were fed with an additional 100 μL of stromal medium after a 2 to 
3 day growth period and the medium was then changed every third day. The plates were 
incubated at 37 °C in a 5% CO2 humidified incubator.  Cells were cultured for a total of 9 days to 
establish colonies, at which time two plates were fixed as outlined below for CFU-F assays while 
the cells in the two remaining plates were maintained in culture with adipocyte differentiation 
media or osteogenic media for CFU-Ad or CFU-Ob assays, respectively, as described below. At 
P2 and P4, the cell seeding densities for the limit dilution assays (in 96-well plates) at these two 
passages were as follows: 5.0 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.13 x 102, 1.56 x 102, 7.8 
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x 101, 3.9 x 101, 1.9 x 101, 0.98 x 101, 0.49 x101, 0.24 x 101.  Otherwise, the limit dilution assays 
were conducted as described for the primary cells. 
 At the conclusion of the studies, the number of wells under each cell density that were 
negative for the specific marker (based on histochemical staining) was determined.  Negative 
staining was defined as a well that failed to contain at least 20 positive cells.  These values were 
then used to compute the frequency of the CFU progenitors according to the formula F = e-x, 
where F is the fraction of colony negative wells, e is the natural logarithm constant 2.71, and x is 
the number of colony forming units per well.  Based on a Poisson distribution of a clonal cell 
lineage, the value of F0 = 0.37 occurs when the number of total bone marrow-derived cells plated 
in a well contains a single colony forming unit.31 
2.2.6 CFU-Fibroblast (F) Assay 
 For CFU-F assays, cells were maintained in stromal medium for a total of 9 days.  
Following incubation, the cells were rinsed twice with prewarmed PBS.  The cells were then 
fixed for 20 minutes in 10% formalin at room temperature and stored at 4°C until staining. The 
cells were stained in 0.1% toluidine blue in 1% paraformaldehyde in PBS for 1 hour and 
subsequently gently rinsed with tap water.  Cells were counted using a phase contrast microscope 
and the MetaVue™ Imaging System (Universal Imaging Corporation, Downingtown, PA, USA) 
and aggregates of >20 toluidine blue staining cells per well were regarded as a positive CFU-F.  
2.2.7 CFU-Adipogenesis (Ad) Assay 
For CFU-Ad assays, cells were first cultured for 9 days in stromal medium to establish 
colonies.  Thereafter, the cells were exposed to an adipogenic induction medium containing 
DMEM-Ham’s F12, 3% FBS, 1% antibiotic/antimycotic solution, biotin (33 μmol/L), 
pantothenate (17 μmol/L), 100nM insulin (1 μmol/L), dexamethasone (1 μmol/L), 
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isobutylmethylxanthine (IBMX) (0.5 mmol/L), rosiglitazone (5 μmol/L) (AvandiaTM, Glaxo 
Smith Kline) and 5% rabbit serum (Invitrogen Corporation, Carlsbad, CA, USA) for 3 days.  
Thereafter, the same medium without the IBMX and the AvandiaTM was used to maintain the 
adipocyte cell culture until day 6 when the cells were fixed for 20 minutes in 10% formalin at 
room temperature and later stained for neutral lipid accumulation with Oil Red O.32,33 The cells 
were stained for 20 minutes followed by 3 rinses with distilled water. With the use of a phase 
contrast microscope, cell aggregates were counted and quantified as CFU-Ad positive if the 
colonies contained >20 Oil Red O positive cells.  
2.2.8 CFU-Osteogenesis (Ob) Assay 
 For CFU-Ob assays, cells were first cultured for 9 days in stromal medium to establish 
colonies.  On day 9, cells were exposed to osteogenic induction medium (DMEM-Ham’s F12, 
10% FBS, 1% antibiotic/antimycotic solution, β-glycerophosphate [10 mmol/L], dexamethasone 
[20 nmol/L] and sodium 2-phosphate ascorbate [50 μg/ml]).  Culture in the osteogenic medium 
was maintained for 5 to 10 days until nodules were detected under phase contrast microscopy. 
The cells were fed 3 times per week.  Upon completion, the cells were rinsed 3 times with 150 
mM NaCl and then fixed in 70% ethanol and stored at 4oC. A 2% Alizarin Red solution was 
prepared in distilled water (pH 4.2) and the cells were stained for 10 minutes at room 
temperature and thereafter rinsed 5 times with distilled water. Cell aggregates were assessed 
under phase contrast microscopy for Alizarin Red staining mineralization and nodule formation. 
2.2.9 Time Line of Differentiation 
Primary cells of all donors were plated in 12-well-plates at 105 cells/cm2 and were 
allowed to incubate for 12 days for time line differentiation experiments and observation 
assessing osteogenesis and adipogenesis. To assess lineage specific differentiation, digital 
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images were obtained daily from each of 6 wells containing induced cells (in adipogenic or 
osteogenic media) and 6 wells containing control cells (in stromal medium). From two donors 
(an 18-month-old Thoroughbred and a 5-year-old Quarter Horse), cells were induced with 
adipogenic medium and cultured in four 12-well plates to day 2, 4, 6 and 10 and subsequently 
fixed and stained with Oil Red O. Cells form the same two donors were also induced with 
osteogenic medium and cultured in four 12-well plates. Based on our experience with human 
adipose tissue-derived stem cells (ASCs)30, which require up to 3 weeks for mineralization to 
occur, it was decided to examine cultures with Alizarin Red staining at day 5, 10, 15 and 20. 
During the cell culture period, daily digital images were taken to monitor adipogenic and 
osteogenic changes of the cells. After the cells were stained, the 12-well plates were digitally 
scanned (Hewlett Packard scanner, USA) and images of the stained cells were taken from each 
plate.  
2.2.10 Statistics 
The values are reported as the mean and standard deviation. All statistical analyses were 
performed using the SAS 9.1.2 software package and the Type I error was maintained at 0.05 for 
all comparisons. The cell doubling data for each passage were compared using Proc GLM and 
the Tukey’s Studentized Range Test for pairwise multiple comparisons of the means. The same 
mean comparisons between passages were performed for the limit dilution assay results (CFU-F, 
CFU-Ad, CFU-Ob) after log transformation of the data. The modeling behavior of the MSC 
doubling number from passage 0 to 10 was determined by regression analysis using Proc Reg.  
2.3 Results 
2.3.1 Cell Doubling Data 
Ficoll separation of bone marrow aspirates collected from the adult horses resulted in the 
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harvest of 6.4 ± 3.4 x 106 nucleated cells/ml of aspirate. The cell viability after thawing 
the liquid nitrogen-stored primary foal MSCs was 64 ± 6%. The cell doubling time for primary 
cells was calculated at 5 ± 1.6 days/cell doubling and is thereby significantly (P < 0.0001) longer 
than the cell doubling time of cells in the subsequent passages (Figure 1-A). There were no 
significant differences between cell doubling times of all subsequent passages, and an average 
cell doubling time of 1.4 ± 0.26 days/cell doubling was calculated for passages P1-P10. There 
was also no significant difference between the cell doubling data of each passage between the 
foals and the population of young adult horses used for this study. By passage 10, the cells had 
undergone 30 ± 2.4 cell doublings (Figure 1-B).  
2.3.2 Cell Morphology Observations 
The cellular morphology of primary cells included both large, widespread, and occasional 
multi-nucleated cells as well as spindle-shaped, mononuclear cells. This degree of heterogeneity 
decreased with subsequent passages as the smaller spindle-shaped fibroblastic cells appeared to 
predominate (data not shown). Cells grown to confluence grew in multiple layers indicating a 
lack of contact inhibition. In subsequent passages, the spindle-shaped fibroblastic cells detached 
more readily during trypsinization, leading to a morphologically homogenous cell population. 
2.3.3 Cell and Time Line Differentiation 
Cell differentiation of MSCs into adipocytes and osteoblasts (Figure 2-B and 2-C) was 
observed in all cultures under the appropriate conditions. A pilot study on adipogenic induction 
and differentiation of equine MSCs showed that the addition of 5% rabbit serum was required for 
consistent adipogenic results. After adipogenic induction, the cell morphology changed within 24 
hours from the elongated confluent fibroblastic cells (Figure 3-A) to more oval-shaped cells, 
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 These granules appeared to develop into fat globules by day 2 (Figure 3-B). It was also noted 
that within 6 to 10 days after induction of adipogenic differentiation these cells were more likely 
to detach.  
The adipogenesis time line differentiation experiment showed that lipid vacuoles became 
more numerous and larger with time (Figure 3-C and 3-D). The most notably visible differences 
occurred between day 0, equivalent to the cellular appearance of the control cells, and day 2 
following induction. 
During the limit dilution assays, osteogenesis of the equine MSCs typically occurred 
within 3 to 4 days after induction. Experiments were terminated when nodules had formed at the 
lowest cell dilutions within the 96-well plates, which on average occurred after 7.4 ± 2.6 days.  
The osteogenesis time line experiment showed rapid mineralization and nodule formation in all 
treatment wells and all plates by day 5 (Figure 4-B) for both donors’ cells. While the control 
wells showed some level of Alizarin Red staining (Figure 4-A), this was minor relative to the 
wells incubated under osteogenic conditions (Figure 4-B).  
2.3.1 Limit Dilution Assays 
Limit dilution CFU-F assays (Figure 3-A) determined that an adherent fibroblastic 
phenotype occurred at a frequency of 1 per 4,224 primary nucleated BM cells (Table 1).  With 
subsequent passage, this population was significantly (P < 0.001) enriched; by passage 2 and 4 
approximately 1 per 2.3-2.5 cells displayed an adherent fibroblastic phenotype (Table 1). CFU-
Ad and CFU-Ob assays yielded frequencies of 1 per 7,114 adipocytes and 1 per 5,605 
osteoblasts per primary nucleated BM cells, respectively. Subsequent passage significantly (P < 
0.001) enriched for progenitors of both lineages. At passages 2 and 4, both lineages were 
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Table 1 – MSC Limit Dilution Assays 
 CFU Frequency (%) 
Passage CFU-F CFU-Ad CFU-Ob 
P0 1:4224 ± 3265* 1:7114 ± 6657* 1:5605 ± 5266* 
P2 1:2.28 ± 0.35 1:2.45 ± 0.01 1:2.45 ± 0.01 
P4 1:2.54 ± 0.2 1: < 2.44 1:3.63 ± 2.37 
 
Table 1 summarizes the frequencies (original data) of colony forming units with fibroblastic 
phenotype (CFU-F), adipogenic capacity (CFU-Ad), and osteogenic capacity (CFU-Ob) within 
the pool of nucleated BM cells at three different passages (P0 [n=5], P2 [n = 5] and P4 [n= 4]). 
Values are expressed as the mean ± standard deviation.  The number of donor animals is 
indicated in parentheses. * indicates statistically significant (P < 0.001) differences from other 
passages of the same CFU assay after log transformation of the data (transformed data not 
shown). The CFU frequencies (> 41%) for adipocytes at passage 4 could not be accurately 





2.4 Discussion  
Bone marrow stromal cells are easily separated from the nonadherent hemopoietic 
fraction of cells by culture and adherence to plastic dishes as early studies on human MSCs by 
Friedenstein34 and Owen35 and their coworkers have shown. The colonies established in 
monolayer culture are derived from a single bone marrow stromal precursor cell, the CFU-F.7,36   
The current study evaluated the growth characteristics and colony forming unit frequencies of 
equine MSCs.  The results of this study document that plastic adherent equine bone marrow-
derived MSCs have a cell doubling rate of 1.4 ± 0.22 days. MSCs show an initial lag phase of 
cell proliferation in primary culture, which increases in subsequent passages similar to that 
documented in other mammalian species. A cell doubling time of approximately 48 hours has 
been reported for dogs22 and Rhesus Macaques26. In humans,  the cell doubling time of postnatal 
MSCs has been reported to be approximately 24 hours.21 Surprisingly, there was no significant 
difference in the cell doubling rate between foals and young horses. It is possible that a greater 
number of animals in each age group would have increased the likelihood of observing a 
difference in the cell doubling time between foals and young adult horses; however, it is also 
plausible that there is no difference in this parameter between donors in these age categories. 
Alternatively, the in vitro culture conditions employed may optimize cell growth independent of 
donor age and mask any inherent differences in doubling time.  Further work will be necessary to 
address these questions. 
Pittenger and his coworkers reported that MSC frequency in human bone marrow of between 1 
per 104 to 1 per 105 nucleated cells.18 Donor age is a factor influencing human MSC frequency.  
Their numbers have been reported to decline in an age-related manner from 1 in 10,000 
(newborns) to 1 in 2,000,000 (an 80 year-old person).37 All of the equine donors used in the 
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current study were young animals for which a higher MSC frequency would be expected. 
Canine22 and feline25 bone marrow-derived MSC frequency has been reported to be 1 in 2.5 x 
104 and 1 in 3.8 x 105, respectively. Our data show an equine MSC frequency among the total 
nucleated BM cells of 1 in 4.2 x 103 (based on CFU-F). However, similar to a report on MSC 
frequency in mice38, considerable variation for primary cell frequencies (up to ten fold) between 
individual subjects was observed in our study. The current study has employed microtiter limit 
dilution assays to assess CFU frequency in the bone marrow.  The values obtained were within a 
factor of 2 of those determined by this technique in murine bone marrow, where CFU-F/Ad/Ob 
frequencies ranged between 1 in 10.8 X 103 to 1 in 3.45 X 104.29  The 1 to 2 orders of magnitude 
discrepancy in the literature reports of bone marrow-derived  equine, human18, canine22, feline25 
and murine38 MSC frequency may be related to differences in the quantitative methods, in 
addition to the age of the donor animals or some biological features unique to a particular 
species. Other studies have calculated CFU frequencies by plating at densities between 103 to 105 
nucleated cells per cm2 and monitoring colony formations by visual inspection after set periods 
of time.25  The combination of low plating density and large culture volume may influence cell 
survival relative to microtiter conditions.   
Following plating and the initial plastic adherence, the low frequency of the primary CFU 
populations was greatly enriched which was the reason for the reduced seeding density in the P2 
and P4 analyses relative to the initial aspirate.  These techniques were designed based on our 
observations using adipose-derived stem cells from human fat in which subcultivation has been 
found to enrich the presence of stromal cell surface markers such as CD13, CD29, CD44, CD73 
and CD90 to > 90% on ASCs populations compared with < 54% of the initial primary stromal 
vascular fraction cells.39  
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In addition to MSC frequency, the expansion characteristics of MSCs documented as cell 
doubling time and number during the early passages provide information relevant to tissue 
engineering applications that will require large cell numbers, especially where scaffold seeding is 
anticipated. The cell doubling time of 1.4 days/cell doubling approximates that of other species 
such as humans, dogs22 and Rhesus Macaques26. However, it has been documented that the 
proliferation rate and maintenance of multipotentiality of human MSCs is dependent on the cell 
plating density in culture.40,41 Thus, it is important to standardize the isolation and expansion of 
MSCs. In our laboratory, a routine plating density of 5 x 103 cells/cm2 was employed based on 
previous studies using human adipose-derived stem cells.39 A recent report42 showed that human 
bone marrow-derived MSCs (passage 3) seeded at 10 cells/cm2 expanded approximately 500-
fold within 12 days with a maximum cell doubling time of approximately 10 hours.  When the 
same cells were seeded at 1,000 cells/cm2, they expanded only 30-fold, which merely resulted in 
a 5-fold greater final cell count relative to the low density plating.  
Sekiya42 and his coworkers also showed significantly reduced absorbance levels for Oil 
Red O after isopropyl alcohol extraction for passage 3 human MSCs that were seeded at 1,000 
cell/cm2 compared with those seeded at 50 cells/cm2.  Furthermore, the length of pre-incubation 
(7 vs. 12 days) prior to adipogenic induction also influenced the degree of differentiation42. This 
illustrates that further work will be required to optimize the seeding density and culture period to 
maximize stem cell yield. 
Established adipogenic differentiation protocols43 have lately been further optimized for human 
bone marrow- and adipose tissue-derived MSCs. These protocols typically contain a mixture of 
insulin, dexamethazone, 1-methyl-3-isobutylxanthine and indomethacin.18,43,44 More recently, 
this protocol has been modified in our laboratory39 replacing indomethacin with rosiglitazone (5 
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μM), which is a member of the hypoglycemic drugs, thiazolidinediones or glitazones.45 These 
agents are used in humans for Type 2 diabetes due to their selective agonistic action on PPAR 
gamma nuclear receptors and thereby increasing insulin sensitivity.45 The same substitution was 
also adopted for the equine MSC cultures. Initial work using the same protocol as commonly 
used in our laboratory39 for human adipose-derived stem cells resulted in limited adipogenesis of 
the equine MSCs. Previous reports found that rabbit serum enhanced adipogenesis in vitro for 
human,44,46-48 rat48 and mouse48 MSCs. Janderova et al44  showed that by using 15% rabbit serum 
instead of fetal bovine serum approximately 90% of all human MSCs were Oil Red O positive 
within 6 days after adipogenic induction. Our studies demonstrated that the addition of 5% rabbit 
serum significantly improves adipogenesis in the equine MSCs in a comparable manner.  
In conclusion, the current work documents the frequency and growth characteristics of 
multipotent equine bone marrow-derived MSCs from foals and young adult horses.  Based on the 
CFU-F frequency of 1 in 4,224 (0.026%) within the nucleated cell pool, and an average yield of 
64 million nucleated cells per 10 ml of bone marrow aspirate, it is feasible to obtain 1.664 X 104 
primary MSCs.  Over a 23-day culture period equivalent to 14 cell doublings, a 16,384-fold (214) 
cell expansion would yield approximately 250 million progenitor cells per 10 ml of bone marrow 
aspirate. Limited data are currently available concerning the number of cells required for the 
repair of tendon defects and strain injuries. However, efforts to repair skeletal defects in canine 
models have shown that 15 million cells/ml of implant volume were sufficient to obtain 
significantly improved bone production and regeneration.49 These calculations are supported by a 
study by Muschler and Midura15 who introduced a mathematical model, which calculated that 70 
million osteoblasts would be required to produce a cubic centimeter of bone.  Further work will 
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CHAPTER 3.  
CHARACTERIZATION OF EQUINE ADIPOSE TISSUE–DERIVED STROMAL 
CELLS: ADIPOGENIC AND OSTEOGENIC CAPACITY AND COMPARISON TO 
















Adult adipose tissue is a source of fibroblast-like precursor cells334-337 capable of 
multipotential differentiation in a number of species. In the human literature these cells have 
gained importance because they are a readily accessible in large quantities.  Recent 
investigations have focused on their application in the emerging field of regenerative medicine 
and surgery. Whereas the nomenclature of these cells varies widely,14 the consensus reached at 
the Second Annual International Fat Applied Technology Society meeting (October 3-5, 2004, 
Pittsburgh, PA) was to use the acronym ‘ASC’ for adipose derived stromal cells23 or adipose 
derived stem cells.24  
The academic and commercial veterinary communities have paid increased attention to 
stromal cells, harvested from adipose tissue (ASC) or bone marrow (MSC), as efficacious 
treatment options for the debilitating and career-ending musculoskeletal injuries and diseases of 
the equine athlete. The human and laboratory animal literature spanning 3 decades provides 
substantial characterization of these cells and their potential application to human diseases. In 
equine veterinary medicine, however, knowledge of equine stromal cells is limited and they are 
currently used with the implicit assumption that their basic characteristics, such as cell doubling 
time and differentiation potential, are similar to those of other species. We have recently reported 
on the frequency and cell doubling characteristics for equine bone marrow-derived MSCs.338 
Similar to other species, equine MSCs rapidly expanded in monolayer culture to quantities 
sufficient for tissue engineering purposes and they exhibited an initial lag phase in culture.338  
Expansion rates of primary cultured murine adipose tissue-derived ASCs have been reported to 
be up to 5-fold faster within the first 5 - 7 days compared with primary murine MSCs.339 Once 
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MSCs have stabilized in culture, their cell doubling time appears to be shorter than that of 
adipose tissue-derived ASCs340 suggesting that differences exist between these 2 cell types. 
Autologous ASCs are relatively quickly isolated from adipose tissue by collagenase 
digestion.341 The resulting stromal vascular cell fraction (SVF) contains a greater proportion of 
stromal/stem cells per unit volume relative to bone marrow. Cell yields from adipose tissue may 
be influenced by age and the harvested tissue site.  Because lesion size in injured tissues, such as 
tendon or bone, may require large amounts of cells for therapeutic efficacy, it is advantageous to 
know the cell doubling times for equine ASCs to optimize therapeutic cell harvest and 
expansion. Whereas the multipotentiality and proliferative rates of equine mesenchymal stromal 
cells derived from equine bone marrow57,208,338 and peripheral blood208 is documented, there is 
limited literature regarding these characteristics for equine adipose-derived mesenchymal cells. 
Our goal was to document the cell doubling characteristics of equine ASCs and their adipogenic 
and osteogenic differentiation potential. 
3.2 Materials and Methods  
Subcutaneous adipose tissue was collected from the region above the dorsal gluteal 
muscles of 5 horses (aged, 9 months to 5 years; mean ± SD, 2.4 ± 1.7 years). There were 4 
Thoroughbred geldings (one 9- and two 18-months-olds and one 3-year-old) and a 5-year-old 
Quarter horse gelding. All chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO) 
or Fisher Scientific International Inc (Hampton, NH) unless otherwise noted.  
3.2.1 Adipose Tissue Harvest 
Horses were sedated with detomidine HCl (0.04 mg/kg intravenously [IV]) and 
butorphanol (0.01 mg/kg IV), the area over the dorsal gluteal muscles was aseptically prepared, 
and skin and subcutaneous tissues were desensitized by local infiltration of 2% lidocaine using 
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an inverted L-block. A 10–15 cm incision was made parallel and ~15 cm abaxial to the vertebral 
column. Approximately 15 mL of adipose tissue were harvested over the superficial gluteal 
fascia for immediate ASC isolation and the skin incision apposed with nylon suture material.  
3.2.2 ASC Isolation Method 
The ASC isolation procedure was based on the technique previously reported for human 
ASC isolation.342 Adipose tissue was minced with a surgical blade, washed and briefly agitated 
with an equal volume of phosphate buffered saline (PBS) solution to promote separation into 2 
phases. The upper phase consisted of the minced and washed adipose tissue and the liquid 
infranatant containing hemopoietic cells suspended in PBS was removed. The tissue was then 
digested in an equal volume of a filtered (0.2 μm) PBS solution containing 1% bovine serum 
albumin (BSA Type V; Sigma-Aldrich) and 0.1% of collagenase (Type I; Worthington 
Biochemical, Lakewood, NJ) with continuously shaking at 37°C for ~50 minutes. Subsequently, 
the sample was centrifuged at 260 g for 5 minutes. To complete stromal cell separation from 
primary adipocytes the sample was briefly and vigorously agitated again and then centrifuged at 
260 g for 5 minutes resulting in a stromal-vascular fraction (SFV) pellet, which contains the 
nucleated cell portion of the adipose tissue harvest and therefore the ASCs.  
A supernatant composed of oil, primary adipocytes and collagenase solution was 
removed after centrifugation and the SVF was  resuspended in 10 mL stromal medium. The SVF 
is the remaining nucleated cell fraction of adipose tissue which contains the mesenchymal 
stromal cells. A small aliquot of the cell suspension was centrifuged and the pellet was 
resuspended in an equal volume of a red cell lysing buffer (Sigma-Aldrich) for ~20 minutes. This 
extended exposure period resulted in the lysis of both erythrocytes and nucleated cells 
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facilitating nuclear trypan blue staining and therefore hemocytometer assessment of total  
nucleated cell numbers per unit volume of adipose tissue. 
3.2.3 Cell Doubling Method 
The cell doubling method and calculations described previously338 were used. Fresh 
primary nucleated cells from the SVF from each of the 5 horses were cultured in duplicate for 
each passage. Cells were plated in stromal culture medium at a density of 5 x 103 nucleated 
cells/cm2 in T25 culture flasks (Corning®, Corning, NY). The adherent cell layer was rinsed 2 
days later with warm PBS to remove any contaminating blood cells and the stromal medium was 
changed every 3 days until the adherent cell population reached ~80% confluence. Adherent 
primary ASCs were then passaged by digestion with 0.05% trypsin, and counted. Subsequent 
passages (P1 - P10) cells were inoculated in T25 flasks at 5 x 103 ASCs/cm2 and allowed to 
multiply for 4 - 5 days to ~70-80% confluence before trypsinization and successive passage.   
Cell doubling times (DT) and numbers (CD) were calculated from hemocytometer counts and 
cell culture time (CT) for each passage according to the following 2 formulae320: 
(1)   ( ) ( )2lnln if NNCD =  
(2)   CDCTDT =  
 (DT = cell doubling time; CT = cell culture time; CD = cell doubling number; Nf = final number 
of cells; Ni = initial number of cells) 
3.2.4 Colony Forming Unit (CFU) Assays 
 CFU limit dilution assays were performed according to previous methods.97 A portion of 
the original isolated SVF cell pool from the 5 horses was reserved for limit dilution assays to 
quantify colony forming units for fibroblasts (CFU-F), alkaline phosphatase expressing cells 
(CFU-ALP), and cells capable of adipogenic (CFU-Ad) and osteogenic (CFU-Ob) 
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differentiation. The same CFU assays were performed at passage 2 (P2) and 4 (P4). Medium 
exchanges were performed every 2-3 days. Digital images were taken with an inverted phase 
contrast microscope (Nikon TS100F, Nikon Instruments Inc., Lewisville TX) and CoolSpot CCD 
Camera (Nikon Instruments Inc) at each passage and subjectively evaluated for cell morphology, 
distribution, and confluence.  
Primary cells of the SVF, also referred to as passage 0 (P0), as well as cells of P2 and P4 
were plated at 2-fold serial dilutions (5.0 x 103, 2.5 x 103, 1.25 x 103, 6.25 x 102, 3.13 x 102, 1.56 
x 102, 7.8 x 101, 3.9 x 101, 1.9 x 101, 0.98 x 101, 0.49 x101, 0.24 x 101) across the 12 columns of 
96-well plates suspended in 100 μL of stromal medium/well. In total 1 plate for each CFU assay 
(CFU-F, CFU-ALP, CFU-Ad, CFU-Ob) per passage (P0, P2, P4) per animal were seeded with 
cells. The plates were incubated at 37°C in a 5% CO2 humidified incubator and the medium was 
changed every 2-3 days. Cells were cultured for 9 days to establish colonies, at which time the 
plates were fixed as outlined below for CFU-F and CFU-ALP assays, while the cells in the 2 
remaining plates were maintained in culture and induced with adipocyte differentiation media or 
osteogenic media for CFU-Ad or CFU-Ob assays, respectively. 
 At the conclusion of the studies, the number of wells under each cell density that were 
negative for the specific marker (based on histochemical staining) was determined.  Negative 
staining was defined as a well that failed to contain at least 20 positive cells (CFU-F, CFU-Ad) 
or one bone nodule (CFU-Ob). These values were then used to compute the frequency of the 
CFU progenitors according to the formula F = e-x, where F is the fraction of colony negative 
wells, e is the natural logarithm constant 2.71, and x is the number of colony forming units per 
well.  Based on a Poisson distribution of a clonal cell lineage, the value of F0 = 0.37 occurs when 
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the number of total adipose tissue-derived cells plated in a well contains a single colony forming 
unit.321  
 All cells used for the CFU assays were initially cultured in stromal medium for a total of 
9 days. The cells assigned to the CFU-F and CFU-ALP assays were fixed and stained on day 9 
and those in CFU-Ad and CFU-Ob cultures were induced at that time into the intended cell line 
as described below. 
3.2.5 CFU-Fibroblast (F) Assay 
 Cells were rinsed twice with prewarmed PBS, fixed for 20 minutes in 10% formalin at 
room temperature and stored at 4°C until staining. The cells were stained in 0.1% toluidine blue 
in 1% paraformaldehyde in PBS for 1 hour and subsequently gently rinsed with tap water. Cells 
were counted using a phase contrast microscope and the MetaVue™ Imaging System (Universal 
Imaging Corporation, Downingtown, PA) and aggregates of >20 toluidine blue staining cells per 
well were considered a positive CFU-F.  
3.2.6 CFU-Alkaline Phosphatase (ALP) Assay 
 Cells were rinsed twice with prewarmed PBS, fixed in 100% ethanol and stored at 4°C 
until staining.  Thereafter, the cells were incubated for 1 hour in the presence of a solution 
containing 5-Bromo-4-chloro-3-indolyl phosphate dipotassium/nitrotetrazolium blue chloride 
(BCIP/NBT), which stains ALP positive cells purple. The plates were rinsed with water and cell 
aggregates were quantified with phase contrast microscopy and regarded as CFU-ALP positive if 
>20 cells stained for ALP.  
3.2.7 CFU-Adipogenesis (Ad) Assay 
Cells were exposed to an adipogenic induction medium containing DMEM-Ham’s F12, 
3% FBS, 1% antibiotic/antimycotic solution, biotin (33 μmol/L), pantothenate (17 μmol/L), 
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100nM insulin (1 μmol/L), dexamethasone (1 μmol/L), isobutylmethylxanthine (IBMX) (0.5 
mmol/L), rosiglitazone (5 μmol/L) (AvandiaTM, Glaxo Smith Kline, Cidra, Puerto Rico) and 5% 
rabbit serum (Invitrogen Corporation, Carlsbad, CA) for 3 days. Thereafter, the same medium 
without the IBMX and the AvandiaTM was used to maintain the adipocyte cell culture until day 6 
post-induction when the cells were fixed for 20 minutes in 10% formalin at room temperature 
and later stained for neutral lipid accumulation with Oil Red O.322,323  The cells were stained for 
20 minutes followed by 3 rinses with distilled water. Phase contrast microscopy was used to 
count cell aggregates quantified as CFU-Ad positive if the colonies contained >20 Oil Red O 
positive cells.  
3.2.8 CFU-Osteogenesis (Ob) Assay 
 Cells were exposed to osteogenic induction medium (DMEM-Ham’s F12, 10% FBS, 1% 
antibiotic/antimycotic solution, β-glycerophosphate [10 mmol/L], dexamethasone [20 nmol/L] 
and sodium 2-phosphate ascorbate [50 μg/ml]).  Culture in the osteogenic medium was 
maintained for 5-10 days until nodules were detected with phase contrast microscopy and the 
culture medium was changed every 3 days.  Upon completion, the cells were rinsed 3 times with 
150 mM NaCl and then fixed in 70% ethanol and stored at 4oC. A 2% Alizarin Red solution was 
prepared in distilled water (pH 4.2) and the cells were stained for 10 minutes at room 
temperature and thereafter rinsed 5 times with distilled water. Cell aggregates were assessed with 
phase contrast microscopy for Alizarin Red staining mineralization and nodule formation. 
3.2.9 Time Line of Differentiation 
Primary cells of all donors were plated in 12-well-plates at 105 cells/cm2 and were 
allowed to incubate for 12 days for time line differentiation experiments and observation 
assessing osteogenesis and adipogenesis. To assess lineage specific differentiation, digital 
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images were obtained daily from each of 6 wells containing induced cells (in adipogenic or 
osteogenic media) and 6 control wells containing cells, which were maintained in stromal 
medium in the absence of inductive factors. For the adipogenic timeline differentiation 
experiment cells from 2 of 5 horses (18-month-old Thoroughbred, 5-year-old Quarter Horse) 
were plated in 12-well plates, induced with adipogenic medium and cultured to day 2, 4, 6 or 10 
and subsequently fixed and stained with Oil Red O. Similarly, cells from the same two donors 
were prepared for osteogenesis timeline experiments and induced and cultured in osteogenic 
medium. Based on our experience with human adipose tissue-derived stem cells14, which require 
up to 3 weeks for mineralization to occur, it was decided to examine the osteogenic cultures with 
Alizarin Red staining at day 5, 10, 15 and 20. During the cell culture period, daily digital images 
were taken to monitor adipogenic and osteogenic changes of the cells. After the cells were 
stained, the 12-well plates were digitally scanned (CanonScan8400F, Canon, Lake Success, NY) 
and images of the stained cells were taken from each plate.  
3.2.10 Statistical Analysis 
Cell culture data for ASCs were compared where appropriate to those recently reported 
on equine MSCs338, which were harvested at the same time from the same horses. Values are 
reported as mean ± SD. All statistical analyses were performed using the SAS 9.1.2 software 
package (SAS Institute Inc., Cary, NC) and the Type I error was maintained at .05 for all 
comparisons.  
Cell doubling data for each passage were compared using PROC GLM and the Scheffe’s 
test for pairwise multiple comparisons of the means. The modeling behavior of the MSC 
doubling number from passage 0 - 10 was determined by regression analysis using the PROC 
REG procedure. PROC GLM and Tukey’s Studentized Range Test was used for mean 
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comparisons of the limit dilution assay results (CFU-F, CFU-ALP, CFU-Ad, CFU-Ob) after log 
transformation of the data.  
3.3 Results  
The stromal vascular fraction provided a pool of primary nucleated cells (Fig 5A). The 
adherent cells presented in a mononuclear spindle-shaped form and appeared numerous and 
loosely distributed across the plates within 24 hours after plating.  
3.3.1 Cell Doubling Data 
The adipose tissue harvest yielded 3.0 ± 1.4 x 105 nucleated cells/ml of tissue (n = 5). The 
cell doubling times across 10 passages (Fig 6A) had no significant differences between all 
passages and the overall mean DT across 10 passages was 2.1 ± 0.9 days/CD. By P10 the cells 
had undergone 28 ± 2 CDs (Fig 6B).  
3.3.2 Adipogenic and Osteogenic Differentiation and Time Line Data 
During 10 days in culture, equine ASCs had robust cell differentiation into adipocytes 
(Fig 7A to D) compared with non-induced cells (Fig 7E to H) in the control wells. Oil-Red-O 
staining of the control cells was negative indicating that there was no visible spontaneous 
adipogenesis. Successful adipogenesis required the addition of 5% rabbit serum as previously 
reported for equine MSCs.338 The cell morphology of the induced ASCs changed within 24 
hours, displaying a distinct ring of dark coarse granules around the cell periphery, which 
developed into fat globules by day 2 after induction (Fig 5 Image C). Equine ASCs also had 
consistent mineralization and alizarin red positive calcium phosphate nodule formation, which 
occurred on average within 12 ± 3.8 days after induction of the ASCs. 
3.3.3 Alkaline Phosphatase Expression 































r 48 hours a
113 
genesis 





s seen in Pan
nification) a
ll population
age C) 24 h
ogy and arr
nd to be oil
el III.  
fter 3 days 























 – Cell Dou
were compi
etic mean ±
sage 8 – 10 
 model (y =







 1.73 + 0.36
ys/cell doub
By passage 

















(y = 2.24 + 
ry and Pass
 young hor












28 ± 2 cell d




























. At this tim




l stem cells 

























 for days 2,
scale of 100
 9 days until
n medium a
ication) of O









ALP expression was remarkably greater in undifferentiated cells of all primary MSC cultures 
and those of all subsequent passages (P2 and P4) compared with ASC cultures (Fig 8). ALP 
staining was visible with the naked eye in all CFU-ALP assays on MSCs across all passages 
compared with those conducted for ASCs where staining was present but detectable only with 
microscopy.  
3.3.5 Limit Dilution Assays 
The adherent fibroblastic cell frequency in the stromal vascular fraction was 1 in 2.3 ± 0.4 
primary nucleated cells as determined by the limit dilution CFU-F assays (Fig 9A).  At P2 and 
P4, the frequency of cells with the fibroblastic phenotype did not change significantly. CFU-Ad 
and CFU-Ob assays for ASCs (Table 2) determined frequencies within the primary nucleated 
stromal vascular fraction cell population of 1 adipocyte progenitor per 4.9 ± 5.4 nucleated cells 
and 1 osteoblast progenitor in < 2.5 ± 0.01 nucleated cells , respectively. Even the lowest dilution 
of primary nucleated cells seeded at 2.4 cells/well was not sufficient to reach the limit dilution 
necessary to calculate the CFU-Ob frequency at P0, as cell expansion and osteogenic induction 
still resulted in nodule formation. Subsequent passaging did not significantly enrich for 
progenitors of either the adipogenic or osteogenic lineage. In the stromal vascular fraction, CFU-
ALP assays revealed a frequency of 1 in 3.64 ± 1.29 primary nucleated cells, whereas subsequent 
passages had significantly lower frequencies (P2: 1 in 97.3 ± 74.95; P4: 1 in 114.86 ± 132.61; 
Table 2). CFU-ALP and CFU-Ob did show significant differences at P2 and P4. ALP expression 
in bone marrow MSC cultures had frequencies for P0 of 1 in 15,035 ± 11,981, which was 
significantly lower when compared with P2 (1 in 4.53 ± 4.91) and P4 (1 in < 2.44), consistent 
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Table 2 – ASC Limit Dilution Assays 
 CFU Frequency (%) 
 ASCa MSCb 
Passage CFU-F CFU-Ad CFU-Ob CFU-ALP CFU-ALP 
P0 1:2.3 ± 0.4 1:4.9 ± 5.4 1: < 2.44 1:3.64* ± 1.29 1:15,035† ± 11,981 
P2 1:6.36 ± 3.76 1:6.52 ± 5.2 1:3.73 ± 1.48 1:97.3§ ± 74.95 1:4.53 ± 4.91 
P4 1:2.54 ± 0.2 1: 4.32 ± 2.46 1:4.83 ± 5.34 1:114.86§ ± 132.61 1: <2.44 
aAdipose tissue-derived stromal cells (ASC), bBone marrow-derived stromal cells (MSC) 
This table summarizes the frequencies (original data expressed as the arithmetic mean ± SD) of 
adipose tissue-derived colony-forming units determined by CFU-F, CFU-ALP, CFU-Ad, and 
CFU-Ob assays, as well as CFU-ALP frequency assays for bone marrow-derived colony forming 
units. Donor horses = 5 for all assays.  
*Indicates statistically significant (P < .001) differences from other passages of the same CFU 
assay after log transformation of the data (transformed data not shown). §Statistically significant 
differences (P < .001) were found for ASC cultures between CFU-ALP and the other assays 
within the same passage. CFU-ALP data for MSC cultures, which have been seeded and cultured 
as previously described338, are reported in this table. †Statistically significant differences (P< 
.001) for MSC CFU-ALP assays were detected between P0 and the subsequent passages (P2 and 
P4). Insufficient dilutions prevented CFU frequencies calculations for osteoblastic lineage 




3.4 Discussion  
We designed this study to determine cell doubling times of equine adipose-derived ASCs 
and to establish that these cells retain their bipotentiality with subsequent passaging. This dataset 
was directly compared with equine MSCs338 because the 2 cell types were harvested and isolated 
in parallel studies from the same donor horses and cultured under the same conditions. 
The cell morphology of SVF cells in primary cultures appeared heterogeneous in nature, yet 
compared with primary nucleated cell populations isolated from bone marrow SVF cells did not 
form distinct colonies but displayed a more uniform distribution upon adhering to the culture 
dish. Considerably fewer cells with a non-fibroblastic morphology were evident in the primary 
ASC cultures as compared with MSC primary cultures. The fibroblastic phenotype of ASCs was 
very similar to that of MSCs. ASCs did not display a lag period in their initial expansion rates as 
had been observed with MSCs.338  
Cell quantification of primary SVF nucleated cells in a population of middle-aged 
humans with mean body mass indexes of ~24-26 are reported to vary from ~300,00014 - 
404,000342 cells/mL of lipoaspirate, values comparable to the present equine results.342 
Consistent tissue collection and laboratory techniques are pivotal for maximizing cell yields as 
the number of adherent human SVF cell was found to vary significantly depending on the 
collagenase digestion times, sampling size, and sampling location.343 Our equine data showed 
variability in cell numbers ranging from 140,000 - 538,000 cells/mL of adipose tissue, which 
may also reflect donor-dependent differences.   The reason for such individual variability of 
ASCs is yet unknown but it is possible that age or body mass may affect stromal cell numbers in 
adipose tissue. Age has been reported to inversely correlate with human marrow-derived MSC94 
yields, yet there are conflicting reports in the literature concerning human ASC yields and age. 
121 
 
One study failed to demonstrate a correlation between human ASCs yields and age342. In 
contrast, others observed that human stromal vascular cells showed a very significant negative 
correlation between glycerol-3-phosphate dehydrogenase expression and age,344 consistent with 
the conclusion that aging may diminish the number of cells capable of adipogenic differentiation. 
The small population size of the horses we studied was insufficient to provide insight into the 
role of age and weight as correlative variables in determining equine nucleated SVF cell yields. 
Cell doubling time of ~2 days for equine ASCs was more rapid than the ~4 days required by 
human ASCs14 cultured under similar conditions in our laboratory but was comparable to that of 
a recently established adult murine preadipocyte cell line (2 - 2.5 days).345 This suggests that 
there is some variability in ASC DT among species. This interspecies variation may be the result 
of different culture conditions and medium composition. 
The harvest and expansion of both ASC and MSC cells have advantages and 
disadvantages. The harvest of MSCs is cosmetically more acceptable and the initial isolation 
process is less involved compared with that for ASCs. However, the sternal bone marrow 
collection technique commonly used with standing, sedated horses exposes them to potential 
complications like pneumothorax and pneumopericardium.346,347 In addition, it places the 
investigator in a precarious and vulnerable position. Whereas ASCs expand at a slightly slower 
rate compared with MSCs, the significantly greater number of available primary cells makes the 
ASC an interesting prospect for achieving the large cell numbers deemed necessary for tissue 
engineering applications.314 Our data imply that for a 10 mL adipose tissue sample with a yield 
of 300,000 nucleated SVF cells/mL of adipose tissue, the immediate available ASC number at a 
frequency of 43% would be 1.3 x 106/mL. After 21 days in culture, the total ASC number would 
be 1.8 x 109 cells, which is significantly greater than comparable calculations for MSCs.338  
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ASC frequency in our study (43%) is ~10-fold higher than reported for humans.14 It has 
been demonstrated that cell seeding density affects cell doubling rates in human MSCs31 and it is 
therefore likely that this adipose-derived stromal cell type will behave similarly under different 
seeding density conditions. Consequently, there is a need for optimization of seeding density and 
culture period to maximize equine ASC yield.  
Cell seeding density344, culture media, and additives such as thiazolidinediones329 and the 
rabbit serum328 are likely to influence the rate of adipose conversion in equine ASCs. In addition, 
there may be individual-dependent variation in the degree of adipogenic differentiation as it has 
been previously reported for human ASCs from different donors.323 Similar to our previous 
report on MSCs, the addition of rabbit serum was required to achieve any reliable adipogenesis 
and fat droplet accumulation.338 Under the same conditions in the CFU assays, adipogenesis was 
consistently more robust in ASC cultures compared with MSC cultures.  
Differences between these 2 cell types were also noted in the time required for osteogenic 
differentiation.  Time from osteogenic induction based on alizarin red positive nodule formation 
seen in the most diluted wells of the limit dilution assays was significantly longer for equine 
ASCs (12 ± 3.8 days) compared with their MSC relatives (7.4 ± 2.6 days)338; however, equine 
ASCs still appeared to produce bone nodules more rapidly than human ASCs, which required ~3 
weeks.14 These results suggest that equine MSCs appear to have a greater osteogenic potential 
which would be consistent with the differences seen in ALP expression between undifferentiated 
ASCs and MSCs (Fig 1 Panel II). In contrast to our data, De Ugarte and coworkers348 could not 
find any significant differences in osteogenic differentiation capacity between human 
mesenchymal cells derived from adipose or marrow tissue. However, more recently differences 
in the osteogenic potential of human MSCs and ASCs have been reported by Im et al who 
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showed that ASCs expressed significantly less ALP and matrix mineralization during 
osteogenesis overall as compared with MSCs.349 It is interesting that even undifferentiated 
mesenchymal cells from marrow and adipose tissue show such profound differences in ALP 
expression. More detailed molecular work will be required to investigate the apparent reduction 
in ALP expression of undifferentiated ASCs during subsequent passaging and how that may 
affect their osteogenic potential. The CFU-Ob cultures of ACSs appeared to show the same 
frequencies of nodule formation, although matrix mineralization required more time. Future in 
vivo studies testing osteogenic applications will be required to determine the comparative 
efficacy of these 2 cell types, as ASCs may be less robust for such applications or require growth 
factor supplements such as bone morphogenic proteins to achieve the MSC potential, as has 
recently been described for the chondrogenic capacity of human ASCs.350 
Further quantitative analysis will be required to demonstrate differences in  osteogenic 
and adipogenic marker expression between ASCs and MSCs. Studies in the human and murine 
literature suggest that there is an inverse relationship between osteoblastogenesis and 
adipogenesis.351,352 Transcriptional processes such as those mediated by the peroxisome 
proliferator activated receptor gamma have been implicated.167 Ligands of this receptor are 
known to activate adipogenesis and promote inhibition of osteogenesis by down-regulation of the 
osteoblast transcriptional regulatory protein Cbfa-1.190 Future investigations may lead to a more 
intricate knowledge of osteogenic disturbances related to delayed or non-union complications in 
equine bone healing and possibly to pharmacological and/or cell-based therapeutic interventions 
for such skeletal healing defects.   
We concluded that equine adipose tissue-derived ASCs are capable of adipogenic and 
osteogenic differentiation and display expansion characteristics similar to those reported in the 
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murine literature. Equally important are the differences noted between the 2 equine stromal cell 
types, the ASC and MSC, for their adipogenic and osteogenic capacity and their pre-
differentiation ALP expression. These findings have potential relevance to future equine 
veterinary tissue engineering and regenerative medical therapies.  
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CHAPTER 4.  
COMPARISON OF CHONDROGENIC POTENTIAL IN EQUINE MESENCHYMAL 






4.1 Introduction  
The two most common types of adult equine stem cells currently used for regenerative 
tissue repair are those derived from bone marrow (mesenchymal stem cells, MSC) and adipose 
tissue (adipose-derived stem cells, ASC). Both cell types are readily accessible in the horse for 
isolation, enrichment, and expansion. The multipotentiality of both cell types with respect to 
adipogenesis and osteogenesis has been documented.1-5 While in vitro chondrogenic potential 
has been described for equine MSCs, little attention has thus far been directed toward equine 
ASCs. Our recent work on the osteogenic and adipogenic potential of MSCs4 and ASCs5 has 
shown differences in cell frequency and in vitro growth characteristics, as well as the ability to 
express alkaline phosphatase and to produce bone nodules during osteogenesis. These results 
suggest inherent differences between MSCs and ASCs during adipogenesis and osteogenesis.  
Studies by Im and coworkers6 in rodent models showed that ALP staining and the amount of 
mineralized matrix deposition during osteogenesis was greater for MSCs compared with ASCs. 
Furthermore, they reported that ASCs appeared to have reduced chondrogenic potential relative 
to MSCs, based on the quantity of matrix production and cell morphology. Bone morphogenic 
proteins are a subgroup of the transforming growth factor superfamily and act as signaling 
factors which regulate cartilage and bone formation. Human ASCs showed reduced expression 
of the bone morphogenic proteins BMP-2, -4, and -6 relative to MSCs and did not express TGFβ 
receptor-1 mRNA.7 Consequently, greater concentrations of TGFβ did not enhance 
chondrogenesis of ASCs and only in combination with BMP-6 did ASCs express gene profiles 
similar to differentiated MSCs. It has also been reported that BMP6 enhances in vitro 
chondrogenesis of MSCs.8,9  Transforming growth factor beta-1 (TGF-β1) used in combination 
129 
 
with insulin like growth factor-1 (IGF-1) appears to enhance chondrogenesis in equine MSC 
cultures based on proteoglycan formation and procollagen Type II mRNA synthesis.10  
Based on human and rodent models, it is important to evaluate potential differences 
between equine MSCs and ASCs and to establish which cells may be optimal for specific 
regenerative tissue applications. The aim of this study was to compare the chondrogenic potential 
of equine ASCs and MSCs pellet cultures in the presence or absence of a robust growth factor 
stimulus and to establish potential differences in their extracellular matrix composition. 
4.2 Materials and Methods  
4.2.1 Materials 
All chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO) or Fisher 
Scientific International Inc (Hampton, NH) unless otherwise noted.  
4.2.2 Animals and Signalment 
Subcutaneous adipose tissue was harvested from the region above the dorsal gluteal 
muscles from 6 young Thoroughbred geldings (mean ± SD, 3.5 ± 1.1 years) and sternal bone 
marrow was collected from a different group of 5 Thoroughbred geldings (mean ± SD, 4 ± 1.4 
years). The procedures were approved by the Institutional Animal Care and Use Committee prior 
to initiation of this study.  
4.2.3 Cell Culture Studies  
4.2.3.1 Bone Marrow Aspiration 
The methods used for bone marrow aspiration11 and MSC isolation12,13 have been 
reported.  Briefly, young horses were selected from the research herd and after sedation with 
detomidine HCl (Domosedan® 0.04 mg/kg IV) the sternum was aseptically prepared and local 
anesthetic (2% Lidocaine, 3 ml) was infiltrated into the subcutaneous tissue. A 10-ml volume of 
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bone marrow aspirate was collected into heparinized syringes (300 IU/ 10ml BM aspirate) using 
a 10-gauge, 3-inch Silverman bone marrow biopsy needle. Marrow stromal cell (MSC) isolation 
and expansion was performed immediately after tissue harvest.  
4.2.3.2 MSC Isolation Method 
Bone marrow aspirates were diluted 1:3 with stromal medium consisting of DMEM-
Ham’s F12 medium (vol/vol, 1:1) (HyClone, Logan, UT, USA), supplemented with a 1% 
antibiotic/antimycotic solution (MP Biomedicals, Irvine, CA, USA) and 10% characterized fetal 
bovine serum (FBS, HyClone) and layered over Ficoll-Paque® PLUS (Stem Cell Technologies, 
Vancouver, BC, Canada). Nucleated cells in the BM aspirate were fractionated over a Ficoll 
density gradient by centrifugation at 1,400 rpm for 30 minutes at 4°C. The MSC-enriched cell 
population above the Ficoll layer was then aspirated and washed in calcium and magnesium-free 
Dulbecco’s balanced salt solution (CMF-DBSS) by further centrifugation at 260 x g for 5 
minutes at 4°C. The washed pellet was then resuspended in stromal culture medium. MSCs were 
expanded in primary culture (P0) to 80% confluence and then stored after cryopreservation as 
described below. 
4.2.3.3 Adipose Tissue Harvest 
Horses were sedated with detomidine HCl (0.04 mg/kg intravenously [IV]) and 
butorphanol (0.01 mg/kg IV), the area over the dorsal gluteal muscles was aseptically prepared, 
and skin and subcutaneous tissues were desensitized by local infiltration of 2% lidocaine using 
an inverted L-block. A 10–15 cm incision was made parallel and ~15 cm abaxial to the vertebral 
column. Approximately 15 mL of adipose tissue were harvested over the superficial gluteal 
fascia for ASC isolation. The skin incision was apposed with nylon suture material.  
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4.2.3.4 ASC Isolation Method 
The ASC isolation procedure was based on a technique previously reported for human 
ASC isolation.14  Adipose tissue was minced with a surgical blade, washed and briefly agitated 
with an equal volume of phosphate buffered saline (PBS) solution to promote separation into 2 
phases. The upper phase consisted of the minced and washed adipose tissue. The liquid 
infranatant containing hemopoietic cells suspended in PBS was discarded. The adipose tissue 
was then digested in an equal volume of a filtered PBS solution containing 1% bovine serum 
albumin (BSA Type V; Sigma-Aldrich) and 0.1% of collagenase (Type I; Worthington 
Biochemical, Lakewood, NJ) with continuously shaking at 37°C for ~50 minutes. The sample 
was centrifuged at 260 g for 5 minutes. To complete stromal cell separation from primary 
adipocytes, the sample was briefly and vigorously agitated and then centrifuged at 260 g for 5 
minutes. After discarding the supernatant containing oil, primary adipocytes and collagenase 
solution, the stromal-vascular fraction (SFV) pellet containing the nucleated cell portion of the 
adipose tissue harvest including the adipose-derived mesenchymal stromal cells (ASCs) was then 
cultured in stromal medium. ASCs were expanded in primary culture (P0) and then stored after 
cryopreservation as described below. 
4.2.3.5 Cryopreservation of Cells 
Post-thaw cell viability is reported to depend on storage concentration and hence all cells 
were frozen at 0.5 million cells/ml after expansion in P0. The cryopreservation medium 
contained 80% fetal calf serum, 10% DMEM, and 10% dimethyl sulfoxide (DMSO).15 Cells 
were placed into a 5100 Cryo 11C Freezing Container (Wessington Cryogenics, Tyne and Wear, 
UK) for 24 hours at -80°C before transfer to liquid nitrogen.  
132 
 
4.2.3.6 Chondrogenesis and Pellet Cultures 
For chondrogenesis experiments, primary cells (P0) were thawed and expanded (P1) to 
obtain approximately 12 million cells for subsequent P2 pellet cultures (n = 30) (Table 1). Cells 
were trypsinized and aliquots of 0.25 x 106 cells (P2) were placed into racked microtubes (ISC 
BioExpress, Kaysville, UT) tubes and centrifuged for 5 minutes at 240 g. The resulting pellets 
were then cultured and induced into chondrogenesis using DMEM/High glucose (10%), 1% 
antibiotic/antifungal solution, dexamethasone (100 nM), ascorbic acid 2-phosphate (50g/ml) and 
ITS+ (culture supplement containing bovine insulin, transferrin, selenous acid, linoleic acid and 
bovine serum albumin [BSA]; BD Biosciences, Bedford, MA) with or without transforming 
growth factor (TGFβ3) (10 ng/ml) and bone morphogenic factor (BMP6) (10 ng/ml). The 3 
treatment groups were as follows: stromal medium (C), chondrogenesis medium (CH), and 
chondrogenesis medium plus TGFβ3 and BMP6 (CHGF).  The medium was changed every 
second day in all cultures. Pellet cultures were terminated at Day 3, 7, 14 or 21 and then prepared 
for compositional studies. The experimental design for the chondrogenesis study is shown in 
Table 1. 
4.2.4 Compositional Analysis  
Pellets were either papain digested for quantification of total DNA and 
glycosaminoglycans (GAG) or fixed in 10% formalin and subsequently embedded in paraffin for 
staining and evaluation with light microscopy. 
4.2.4.1 Histology 
Multiple sections of all pellets were stained with alcian blue to evaluate proteoglycan 
deposition and selected pellets sections were stained with hemotoxylin and eosin to evaluate 
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pellet morphology. Representative sections of the ASC and MSC pellet cultures and their 
treatment groups were read and evaluated by a pathologist (DBP). 
4.2.4.2 Immunohistochemistry 
Immunostaining was performed using an automated immunostainer (Dako Corp., Carpinteria, 
CA). Paraffin-embedded sections were deparaffinized and rehydrated. Endogenous peroxidase 
activity was quenched with H2O2 (3.0%). Slides were pretreated with proteinase K (Dako Corp.) 
for antigen retrieval, blocked with horse serum (30 min) and incubated with the primary antibody 
for 30 min at 25°C. Mouse monoclonal antibody  (Developmental Studies Hybridoma Bank, The 
University of Iowa, Iowa City, IA), reported to cross-react against equine collagen Type II16, was 
diluted 1:5. After rinsing, slides were incubated with horseradish peroxidase-labeled polymer 
(avidin- and biotin-free) conjugated to goat anti-mouse IgG (EnVision, Dako Corp.). Peroxidase 
activity was detected using the NovaRED substrate kit (Vector Laboratories, Inc., Burlingame, 
CA), and tissues were counterstained with Mayer’s hematoxylin. For each tissue, a conditioned 
medium negative control, that did not contain primary antibody, was evaluated and no staining 
was detected. Paraffin-embedded cartilage from the proximal third tarsus (T3) of a 3-year-old 
Thoroughbred gelding was used as a positive control. 
4.2.4.3 Transmission Electron Microscopy 
For transmission electron microscopic (TEM) tissue examination, representative samples 
taken from 3 donors of Day 21 MSC and ASC pellet cultures (C, CH, and CHGF) were used. 
Paraffin-embedded pellets were deparaffinized, rehydrated with water and then fixed, processed 
and embedded in an epon-araldite resin as previously reported.17 Thin sections were prepared 
with an MT XL microtome (RMC Products, Tucson, Arizona), stained with uranyl acetate and 
lead citrate, and observed with an electron optical microscope (JEM-1011, JEOL Ltd.,  
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Table 3 – Chondrogenesis: Experimental Design  
Time Course Analyses C CH CH-GF ASC donors 
MSC 
donors 
Day 3 Histology/Immunohistochemistry1 1 1 1 6 5 
Day 7 Histology/Immunohistochemistry 1 1 1 6 5 
 Biochemical & Pellet Size Analysis 2 2 2 6 5 
Day 14 Histology/Immunohistochemistry 1 1 1 6 5 
 Biochemical & Pellet Size Analysis 2 2 2 6 5 
Day 21 Histology/Immunohistochemistry 1 1 1 6 5 





Total Pellets  10 10 10   
1Immunohictochemistry was performed on tissue from three donors for both MSC and ASC pellet cultures. 
2Paraffin-embedded pellets used for histology were recovered and processed for TEM.  
Cell lines from a total of 5 donors were used for MSC pellet cultures and from 6 donors for ASC 
pellet cultures. A total of 30 pellets per donor per cell type (MSC or ACS) were grown. Pellets 
were analyzed individually for histological examination and pooled by day (2 pellets per donor) 
for the biochemical analysis. Two alcian blue-stained sections per pellet for all donors were used 
to measure cross-sectional pellet size. The pellets were divided into 3 treatment groups as 
follows: stromal medium (C), chondrogenesis medium (CH), and chondrogenesis medium plus 
TGFβ3 and BMP6 (CH-GF) and the medium was changed every third day. Pellets were 




Lewisville, TX). Paraffin-embedded articular T3 cartilage was processed in the same manner and 
used as a positive control. 
4.2.4.4 Total DNA Quantification 
Total DNA within the pellets was assessed with the Hoechst assay as previously 
published.18 Briefly, papain digested pellet DNA concentration was assessed against a calf 
thymus DNA standard curve after preparation in an assay solution (2M NaCl, 50mM sodium 
monobasic phosphate, pH 7.4) containing the Hoechst 33258 dye. Pellet total DNA was 
measured with a spectrophotometer (Synergy HT, Bio-Tek Instruments, Inc., Winooski, VT) and 
used to normalize GAG concentrations. 
4.2.4.5 Glycosaminoglycans Quantification 
Pellets were digested in 100 μg/ml of papain in 0.4 mM sodium acetate (pH 6.8), 10 mM 
EDTA, 200 mM l-cysteine at 60°C for approximately 24 hours. Glycosaminoglycan (GAG) 
synthesis within the pellets was measured by dimethylmethylene blue (DMMB) assay as 
previously described, using chondroitin sulfate C from shark cartilage as a standard.19 
Cross-sectional Pellet Size – The areas of 2 different cross-sections of all alcian blue-
stained pellets from all donors were measured using the Image Pro Software (Cybernetics, Inc, 
Bethesda, MD) after calibration with a micrometer.  
4.2.5 Statistical Analysis  
The study design employed a repeated measures analysis of variance in a split plot 
arrangement of treatments. The main plot was arranged as a 2 by 3 factorial including 2 cell 
types (MSC, ASC), three treatments (C, CH, CHGF) and the cell type by treatment interactions. 
The error term used for the main plot was donor within cell type by treatment. The subplot 
factors included day, day by cell, day by treatment and day by cell by treatment interactions. 
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Tukey’s test was employed for post-hoc main effect comparisons and the T test was used for 
pair-wise comparisons of the least square means to examine the interaction effects. All statistical 
analyses were performed using the Proc GLM procedure of the SAS 9.1.2 software package 
(SAS Institute Inc., Cary, NC) and the Type I error was maintained at α = .05 for all 
comparisons. Data are presented as the arithmetic mean ± standard error in all figures. 
4.3 Results  
4.3.1 H&E and Alcian Blue Histology 
Histological examination of pellets stained with H&E showed that those cultured from 
MSCs produced a hyaline cartilage-like morphology by Day 14 (Fig. 10) based on characteristic 
lacunae formation containing round chondrocytes typically associated with maintenance of 
chondrogenesis.20 Pellets grown from ASCs maintained an immature fibroblastic tissue 
appearance for the duration of the study. MSC pellets showed consistently more intense 
proteoglycan staining than ASC pellets (Fig. 11). Mild alcian blue staining was notable as early 
as Day 3 in MSC pellets treated with growth factors, but was not apparent in ASCs until Day 14. 
Under chondrogenic conditions without added growth factors, proteoglycan staining was less 
intense for both cell types but MSC differentiated pellets showed proteoglycan staining by Day 
7, which was a week earlier than for ASCs. 
ASCs under chondrogenic conditions without growth factors pellets showed fibrillar 
matrix by Day 7. The outer pellet layers were often composed of cohesive and spindeloid cells 
arranged parallel to the surface varying in thickness from 3 to 10 cells. Inner layers tended to 
palisade and were variably arranged perpendicular to the surface. Under growth factor treatment 
the matrix density of the outer cell layer was increased at Day 14.  Pellets showed a broad 




Figure 10: Hematoxylin and Eosin (H&E) Staining of ASC and MSC Pellets 
The figure shows that pellets cultured from both cell types showed an initial peripheral layer 
formation and maturation by Day 14 in form of a deeper palasading and perpendicular 
arrangement of cells. However, only MSC-grown pellets produced hyaline cartilage by Day 14. 
The appearance of these pellets showed the characteristic lacunae formation containing 
chondrocytes. Pellets grown from ASCs never showed evidence of hyaline cartilage formation 





Figure 11: Alcian Blue Staining of ASC and MSC Pellet Cultures 
Pellets cultured from MSCs showed consistently more intense staining than those cultured from 
ASCs. Mild proteoglycan staining was notable as early as Day 3 in MSC pellets treated with 
BMP6 and TGFβ3 but was not notable in ASCs until Day 14 under the same conditions. 
Chondrogenic conditions without added growth factors led to less intense proteoglycan staining 
for both cell types but MSC differentiated pellets showed proteoglycan staining by Day 7, which 
was a week earlier than was seen for ASCs. The ASC-CH and ASC-CHGF pellets of Day 14 





in thickness. By Day 21 only one of the ASC pellets showed moderate amounts of dense hyaline 
extracellular matrix, which was not birefringent. Moderate alcian blue staining of extracellular 
matrix by Day 14 suggests proteoglycan expression in the stroma. 
MSC pellets without growth factor treatment developed several layers of spindle cells 
arranged parallel to the surface by Day 3. Palisading spindle cells were arranged perpendicular to 
the surface. No extracellular matrix was seen, yet mild alcian blue staining was noted in the 
peripheral zone in CHGF MSC pellets. Within 4 days the outer zone showed spindle cells layers 
vary from 3 to 10 cells in thickness arranged parallel to the surface surrounded by moderate 
fibrillar extracellular matrix.  There was no alcian blue staining of the outer zone of Day 7 MSCs 
pellets but moderate staining of the matrix in the deeper layers. Partial chondroid differentiation 
was noted, characterized by abundant extracellular matrix with round to stellate cells, often 
located within the lacunae and organized into rows perpendicular to the surface. Intense alcian 
blue staining was seen in the deeper cartilaginous appearing zone by Day 14 and the bulk of the 
pellet showed prominent chondroid differentiation.  The matrix was eosinophilic near the surface 
but the thick chondroid differentiated zone appeared hyaline-like, typical of cartilaginous matrix 
and was only very mildly birefringent. Cells were round to oval and positioned within lacunae. 
Day 21 MSC pellets had a similar appearance but much of the matrix was birefringent under  
polarized light suggesting some collagen type I deposition as hyaline cartilage is usually not 
bifringent. There was evidence of variable central necrosis in most pellets of both cell types by 
Day 14. 
4.3.2 Collagen Type II Immunohistochemistry 
Collagen type II expression was noted by Day 7 in MSC pellets cultured with BMP6 and TGFβ3 




Figure 12: Collagen Type II Immunohistochemistry of ASC and MSC Pellets 
The figure shows convincing Collagen Type II expression in MSC pellets when cultured with 
BMP6 and TGFβ3. ASC pellets did not show any evidence of collagen staining under the same 
conditions and are therefore not shown. Pellet cultures under chondrogenic conditions without 
growth factors showed mild staining by Day 14 whereas ASC pellets again did not express 
antigen for the collagen Type II antibody. All pellets were exposed to conditioned medium 
serving as negative control for unspecific staining and mature cartilage from the proximal 




MSC pellet cultures under chondrogenic conditions without growth factors showed mild staining 
by Day 14 whereas ASC pellets again did not express collagen type II. The positive controls of 
paraffin-embedded cartilage sections stained less intensely for collagen Type II than the pellets, 
presumably because the cartilage sections had previously been decalcified, a process that is 
thought to have affected the cartilage epitopes and therefore affecting antibody binding affinity. 
4.3.3 Transmission Electron Microscopy 
ASC pellets (CH and CHGF treated) from only one of three donors developed any 
appreciable amounts of collagen fibrils, whereas all examined MSC pellets (CH and CHGF; n = 
3 donors) showed abundant collagen fibrils. MSC pellet cultures formed more fibrils and had 
more cohesive areas of extracellular matrix compared to ASC pellets. Collagen fibrils were 
virtually undetectable in the control (C) cultures. It was notable that pellets showed a random 
arrangement of fibrils similar to the transitional cartilage zone of articular cartilage (Fig. 13-E). 
Areas of linear fibril arrangement were seen in pellet cultures of both cell types but it was not 
possible to determine from which pellet layers they originated. MSC pellets (Fig. 13-D) appeared 
to have thinner collagen fibrils compared with articular cartilage (Fig 13-E) as well as less 
interfibrillar extracellular matrix. However, compared with ASC pellets (Fig. 13-B) MSC fibrils 
seemed thicker and more mature.  
No compositional differences were discernable under TEM evaluation between CH and 
CHGF treatments. 
4.3.4 DNA Concentration 
DNA concentrations (Fig. 14) were significantly lower in control pellet cultures 





Figure 13: Transmission Electron Microscopy 
Sections of ASC cultures (CHGF) shown in panel A and B clearly show collagen fibrils at 40k 
and 80k magnification, respectively. Panel C and D represent MSC pellets (CHGF) which had a 
similarly random fibril arrangement as the image of the transitional zone of equine articular 
cartilage (panel E, 40K magnification) but showing less interfibrillar extracellular matrix. Panel 
D (MSC pellet at 80K magnification) shows more mature and thicker fibril structure compared to 
that of ASC pellets (panel B, 80K magnification) but MSC fibrils still appear to have a smaller 




ASCs and MSCs (P < .0001) on Day 7. Significantly lower DNA concentrations were also seen 
for control cultures (P < 0.009) compared to chondrogenic cultures with and without growth 
factors on Day 14 (P < .0001) and 21 (P < .0001) compared to Day 7. The only other significant 
difference found was for control and CH ASC cultures on Day 21 (P = .02).  
4.3.5 GAG Concentration 
GAG concentrations (Fig. 15) normalized to total DNA concentrations were not 
significantly different for any cultures at Day 7. On Day 14, MSCs treated with growth factors 
showed significantly greater GAG concentrations than all other treatments for both cell types (P 
< .0001). On Day 21 MSCs cultured under chondrogenic conditions with and without growth 
factors expressed higher GAG concentrations compared with ASCs grown under the same 
conditions  (ASC-CH vs. MSC-CH, P = .0044; ASC-CHGF vs. MSC-CH, P = .0076; ASC-
CHGF vs. MSC-CHGF, P < .0001).  
4.3.6 Pellet Cross-sectional Measurements 
Cross-sectional pellet size of ASC-derived pellets (Fig. 16) did not vary in any of the treatments, 
with the exception of CH between Day 3 and 21 (P = .0062). Pellet sizes grown from CHGF-
treated MSCs were significantly larger than CH-treated pellets on Days 14 (P = .0032) and Day 
21 (P < .0001). Significant differences in CHGF treatments were found between Days 3 and 7 
(P=.05), approaching significance between Days 3 and 14 (P = .058) and Day 21 was 
significantly different from Day 3 (P < .0001), 7 (P = .005) and 14 (P = .0043). CH-treated MSC 
pellets were larger than ASC pellets grown under the same conditions on Day 7 (P=.013). 
However, MSC pellets were larger compared to ASC pellets on Days 7 (P = .0078), 14 (P < 




Figure 14: Total DNA Concentrations 
ASC pellet cultures of days 7, 14 and 21 and MSC Pellets cultures of days 7 and 14 grown under 
chondrogenic conditions (± growth factors) had significantly greater total DNA concentrations 
compared to their control cultures (P < .0001). The data are represented as the arithmetic mean ± 




Figure 15: Total Glycosaminglycan Concentrations 
Relative DNA corrected GAG concentrations were not significantly different for any cultures on 
Day 7. By Day 14 significant differences were seen between MSCs treated with growth factors 
and all other treatments for both cell types (P < .0001). A week later MSCs cultured under 
chondrogenic conditions with and without growth factors showed significant differences to 
ASCs grown under the same conditions  (ASC-CH vs. MSC-CH, P = .0044; ASC-CHGF vs. 
MSC-CH, P = .0076; ASC-CHGF vs. MSC-CHGF, P < .0001). The data are represented as the 





Figure 16: Pellet Cross-sectional Measurements 
ASC-derived pellet cultures grown with or without growth factors showed no differences in 
cross-sectional pellet areas. Pellet sizes grown from MSCs were significantly different between 
CH and CHGF treatments on Days 14 (P = .0032) and Day 21 (P < .0001). On Day 7 significant 
differences were seen in CHGF treated ASC and MSC pellets (P < .0078). Day 21 MSC pellets 
treated with growth factor (CHGF) were significantly different from those of Days 3 (P < .0001), 
7 (P = .005) and 14 (P = .0043). The comparison of CH treatments between MSC and ASC 
grown pellets showed significant changes only on Day 7 (P=.013). However, comparing CHGF 
treatments between the two cell types showed differences on Days 7 (P = .0078), 14 (P < .0001) 
and 21 (P < .0001). Cross-sectional areas of pellets grown in stromal medium (C) were not 
measured due to the lack of characteristic pellet structure. The data are represented as the 




CH treated cultures decreased significantly (P = .016). A trend in decreasing pellet size was also 
noted for ASCs but was not significant. Pellet sizes were not assessed for control cultures 
because the lack of structural integrity caused a progressive loss of cell material in time despite 
careful media changes. The correlation between GAG corrected for DNA and pellet cross-
sectional area approached significance at a p value of 0.076. 
4.4 Discussion 
The use of stem cells in equine veterinary medicine is beginning to expand to 
applications beyond tendon and ligament repair. MSCs injected directly into joints has 
significantly contributed to the healing process of experimentally induced meniscal lesions in 
sheep, rats and dogs.21-25 The application of stem cells in the traumatized and osteoarthritic 
equine joint was debated at the recent 2007 Symposium of the American College of Veterinary 
Surgeons debated. Results of a clinical study presented at this meeting showed that 10 out 15 
horses suffering from a variety of joint related pathologies with poor prognosis recovered and 
returned to work after cell-based therapy with MSCs.26 It was suggested that MSCs are 
beneficial to articular cartilage recovery as long as the joint surface was not denuded of cartilage 
with evidence of subchondral bone exposure. Furthermore, it was postulated that gene-modified 
MSCs may provide more significant results.26  
The in vitro chondrogenic potential of equine MSCs has previously been documented in 
monolayer cultures10,13,27, three-dimensional fibrin disks10, and pellet cultures.2,3,28,29 In a recent 
study, Kisiday and his coworkers compared chondrogenesis in equine adipose tissue and bone 
marrow-derived progenitor cells.16 The mesenchymal stromal cells were cultured in agarose and 
self-assembling peptide hydrogels with or without the transforming growth factor TGFβ1.16 The 
results of this study were consistent with our data, demonstrating the superiority of bone marrow 
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MSCs in their chondrogenic potential. Similar to our study, equine ASCs demonstrated the 
ability to synthesize extracellular matrix in the form of proteoglycans and glycosaminoglycans, 
yet unlike bone marrow MSCs, the adipose tissue–derived progenitor cells did not demonstrate 
any collagen Type II expression during the 3 week culture period. However, ASCs responded to 
TGFβ1 treatment with elevated levels of hydroxyproline and glycosaminoglycan production in 
peptide hydrogel cultures.16 These results suggest that equine ASCs express receptors to TGFβ1 
or at least may respond to the growth factor through alternate pathways.  
The differences in the chondrogenic potential between the two equine cell types are 
consistent with studies on human and rodent adipose and marrow-derived mesenchymal 
progenitor cells.6,30-32 However, Hennig32 and coworkers recently showed that human ASCs do 
not express significant levels of TGFβ receptor-I mRNA, suggesting that human ASCs do not 
have receptors for TGFβ1. Human ASCs did not respond significantly to culture supplementation 
of TGFβ1 at 10ng/ml or higher concentrations, levels comparable to those used in both in 
Kisiday’s and our current study. However, endoglin (CD105), a component of the TGFβ type I 
and II receptor complex33,  was expressed on both human ASCs34 and MSCs35 as part of their 
surface marker profile. Reports have suggested that dexamethasone36 in chondrogenic protocols 
may suppress any stimulatory effects of TGFβ1  and this may contribute to the observed tissue-
dependent differences between MSCs. 
The growth factor TGFβ3 enhances chondrogenesis due to its putative role in the 
regulation of cell adhesion molecules, cytokines, and cytokine receptor synthesis.37-39 Estes and 
his coworkers have shown that BMP6 and TGFβ3 controlled chondrogenic induction in human 
ASC-derived alginate bead cultures and increased collagen Type II (COL2A1) by 38-fold and 
42-fold, individually, and by 56-fold when used in combination,.40 Also TGFβ3 had significant 
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effects on collagen type X (COL10A1), suggesting a role in hypertrophic collagen synthesis. 
Recent work41 on MSCs derived from equine umbilical cord blood (UCB), reported that TGFβ3 
stimulated chondrogenesis; however, necessary controls were not presented to allow assessment 
of the relative influence of this growth factor on the chondrogenic potential.  
Consistent with Estes et al40 but in contrast to our own findings in the equine model, 
Hennig32 and coworkers found that the addition of BMP6 resulted in similar chondrogenic 
induction of human ASCs and MSCs. If the work by Awad36 and coworkers on human ASCs is 
extrapolated to the equine ASC model, then the relatively higher concentration of 
dexamethasone in our study (100nM) compared to Hennig’s study (20nM) may have inhibited 
chondrogenic differentiation and accounted for the dimished ASC response compared to bone 
marrow MSCs. Regardless, our results indicate that there are inherent differences between these 
two equine cell types.  Receptor profiles of ASCs may differ between these progenitor cells of 
different species. Further investigations will be necessary to determine whether the cytokine 
receptor profiles of equine ASCs and bone marrow MSCs differ and if this could account for 
their differential chondrogenic responses.   
The immunohistochemical staining of collagen type II in MSC pellets demonstrated a 
pattern whereby signal was apparent within the zone below the superficial spindeloid cells layers 
and faded toward the center of the pellet. This pattern may be related to oxygen diffusion and 
may reflect the location of an oxygen tension gradient particularly suitable for chondrocytic 
synthesis of collagen type II fibrils. It is known that articular cartilage in vivo is bathed in joint 
fluid with a relatively low oxygen concentration (~ 5%).42 Proliferation of human adipose tissue-
derived stem cells is inhibited at oxygen tension of 5% but the rate of protein synthesis increases 
by 2-fold and that of collagen synthesis by 3-fold and glycosaminoglycan synthesis and lactate 
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production are increased as well.42 Also, both cartilage thickness and cell density affect oxygen 
tension of in vitro cartilage sections43 and oxygen tension has been associated with the regulation 
of chondrogenic induction and a concomitant decrease in cell proliferation.20 Thus, oxygen 
tension may play a role in the current study and merits further investigation.  
The pellet morphology of equine ASC and MSC cultures showed considerable 
differences. Of note was the significant reduction of MSC pellet sizes under chondrogenic (CH) 
conditions during the second week in culture. Human chondrocytes44 and mesenchymal stem 
cells45 express the contractile protein, α-smooth muscle actin (SMA), which is believed to cause 
in vitro pellet formation46 after chondrogenic induction and is essential to cell-mediated 
contraction leading to tissue remodeling and collagen synthesis. Scaffold designs with variable 
resistance to cell-mediated contraction have been used to show that chondrocytic cell phenotype 
and collagen type II synthesis was superior in scaffolds permissive to contraction.47 Tissue 
remodeling, contraction and cartilage synthesis is enhanced by treating canine chondrocytes 
seeded onto collagen type II-GAG scaffolds with fibroblast growth-factor-2 (FGF-2).48 FGF-2 
has also recently been shown to enhance chondrogenesis in equine mesenchymal stem cells due 
to an anabolic effect on glycosaminoglycan content and collagen type II expression.29 Consistent 
with these reports, the smaller pellet size seen in MSC chondrogenic cultures on Day 14 in this 
study coincided with the appearance of hyaline-like cartilaginous tissue shown in Figure 1. ASC 
pellets, however, showed a similar but non-significant trend in size reduction suggesting some 
degree of tissue remodeling consistent with the glycosaminoglycan deposition and the traces of 
collagen type II synthesis observed using TEM. In contrast the increased size of MSC pellets 
stimulated by BMP6 and TGFβ3 was quite striking, which appeared to obscure the contractile 
effect on pellet matrix remodeling during chondrogenesis and warrants further investigation. 
151 
 
The lack of the characteristic structure of pellets grown in stromal medium (C) prevented 
the measurement of their cross-sectional area. Failure to form a sufficiently robust extracellular 
matrix rendered the control pellets susceptible to cell loss during media changes. Only a few 
cultures in the control medium (C) formed pellets that remained intact for the duration the study; 
of these, most were derived from MSCs. The cellular loss in the control cultures due to media 
change is believed to account for the reduction in DNA content seen on Day 7 in control pellets. 
The ~three-fold reduction in total DNA content evident in CH and CHGF cultures after Day 7 
was attributed to the progressive central necrosis in pellets of both cell types. The lack of 
differences among the normalized GAG concentrations between controls and the treated pellet 
cultures it thought to relate to relative differences in DNA and measured GAG concentrations 
between control cultures and treated cultures.  Additional variation in the data may be due to the 
fact that MSCs and ASCs were isolated from two different populations of horses. 
In summary, our data show that equine bone marrow derived MSCs exhibited superior 
chondrogenic potential compared to ASCs in the presence of stimulatory growth factors. 
Nevertheless, the easy access to ASCs in the horse makes these cells an attractive choice for 
tissue engineering purposes. Further  investigations of receptor profiles of equine ASCs and 
MSCs are needed in order to optimize cell selection for the purpose of regenerative tissue repair 
and cartilage resurfacing in the horse. 
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CHAPTER 5.  





The significance of these studies is that stem cells from equine bone marrow and adipose 
tissue can be reliably harvested, isolated and expanded to large numbers in relatively short 
periods. In vitro cell growth characteristics and differentiation multipotential provides a basis for 
the study of these cells in association with scaffold materials and cell-based therapeutic 
techniques. The data demonstrate that there are differences between the two cell types with 
respect to cell growth, cell marker expression and their differentiation potential, which will 
require further investigation to optimize culture conditions and determine receptor profiles to 
maximize their use for tissue engineering purposes. 
Our studies have shown that MSCs and ASCs occur more frequently in bone marrow and 
adipose tissue compared with other species. However, the frequency data is quite variable and 
the population size was limited making it difficult to predict cell frequencies accurately. Both 
cell types exhibited robust adipogenesis and osteogenesis; however, osteogenesis occurred more 
rapidly in MSCs compared to ASCs. Undifferentiated MSCs expressed more ALP than ASCs, 
which would support the notion that MSCs are better equipped for osteogenesis compared with 
ASCs. Likewise, adipogenesis appeared more robust in ASC cultures compared with MSC 
cultures. These observations will require further molecular assessment but are consistent with the 
natural environment of these two cell types. Similar to other species both MSCs and ASCs 
maintained differentiation potential during later passages. 
MSCs showed superior chondrogenic potential based on histological morphology, 
collagen type II immunohistochemistry and proteoglycan expression.  Pellet morphology of 
MSCs was much more reminiscent of hyaline cartilage than the matrix organization of pellets 
grown from ASCs. Proteoglycan expression in ASC pellets compared with the controls suggests 
that these cells do respond to chondrogenic culture media and that BMP6 and TGFβ3 have an 
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additional positive affect on ASC differentiation and pellet maturation. However, the lack of 
collagen Type II expression and the morphological immaturity of ASC pellets suggest that ASCs 
may require different culture conditions and/or additional stimuli to perform similarly as MSCs. 
Under the present conditions the bone marrow derived stromal cells clearly show superior 
chondrogenesis as early as Day 7. Receptor expression profiles will need to be studied in the 
future to elucidate culture requirements for these two cell types to optimize the use of ASCs and 
MSC in tissue engineering. The high cell numbers that could easily be harvested in horses makes 
these cells a potential source of cell for regenerative tissue repair purposes. Future studies will be 
directed at optimization of their use in tissue engineering.   
Our research efforts thus far, using equine stem cells have mostly concentrated on 
characterizing the in vitro growth and differentiation properties of these cells and we have also 
employed these cells clinically in studies on equine tendonitis. Because we can reliably generate 
large numbers of cells we have established the ground work for additional studies on optimizing 
culture conditions and on the effect of appropriate bioabsorbable scaffolds, cellular gene-
enhancement and mechanoinduction prior to implantation, which may all play an important role 
in enhancing the potential of equine bone marrow and adipose tissue derived stem cells for their 
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Role: PI. Amount: $24,926. 
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Martin Andreas Vidal was born in May 1967, in Boulder, Colorado, where he spent the first 
five years of his life. He then grew up in Munich, Germany, and completed his secondary 
education at the Maximiliansgymnasium in Munich in 1987. After graduation Martin returned to 
the United States to study veterinary medicine. After a year of improving his English language 
skills while working partly as an animal care taker at the School of Veterinary Medicine in 
Madison, Wisconsin, and as a trainer and exercise rider at a racehorse training facility near 
Rhinelander, Wisconsin, he then attended the University of Wisconsin in Madison, earning the 
degree of Bachelor of Science in Meat and Animal Science in 1992. Intrigued by ongoing 
research in nutrition, bone biology and fracture biomechanics at the Department of Meat and 
Animal Science, he decided to extend his education in these areas of interest, successfully 
completing his thesis and earning the degree Master of Science in Meat and Animal Science in 
1995. Thereafter Martin was accepted at the University of Liverpool in England where he 
eventually studied veterinary medicine to earn his Bachelor of Veterinary Science in 2000 and he 
became a member of the Royal College of Veterinary Surgeons in the same year.  
After graduation Dr. Vidal took a locum position as an associate equine veterinarian at the 
Minster Equine Veterinary Clinic in York located in Yorkshire, England. Nine months later, the 
outbreak of the foot and mouth disease in the Spring of 2002 drastically reduced the case load at 
the Minster Equine Veterinary Clinic and prompted Dr. Vidal to relocate to Newcastle upon 
Tyne in Northern England, where he took a position as a Temporary Veterinary Inspector for the 
British Department of Environment, Food and Rural Affairs (DEFRA) at the Kenton Bar, 
Newcastle Disease Emergency Control Center. 
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internship in equine medicine, surgery and reproduction at the Goulburn Valley Equine Hospital 
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